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Abstract 
Statement of problem: Hepatocellular carcinoma (HCC) is a leading cause of cancer-
related death and often arises in the context of hepatic cirrhosis. Transcatheter arterial 
chemoembolization (TACE) is a non-surgical treatment for patients with unresectable 
HCC involving local and targeted intra-arterial delivery of chemotherapy. Currently, it is 
unclear whether overall survival in patients with HCC treated with TACE can be 
predicted by longitudinally measured clinical and imaging biomarkers. The aim of this 
study was to determine whether longitudinally collected metrics might contribute to the 
prediction of overall patient survival. 
Materials and Methods: This IRB-approved cohort study included 211 consecutive 
patients with unresectable HCC treated with TACE between 1/1/2001 and 11/28/2008. A 
complete case analysis was performed on baseline and longitudinally collected clinical 
and imaging data of 119 patients. Baseline (time-independent) and longitudinal (time-
dependent) data included age, gender, ethnicity, type of cirrhosis and Eastern European 
Cooperative Group (ECOG) performance status. Time-dependent data included Child-
Turcotte-Pugh (CTP) score, tumor burden, longest tumor size, portal vein thrombosis, 
tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 
v.1.1 and modified RECIST. Overall survival estimates were calculated by the Kaplan-
Meier method. Cox regression models were used to predict the effect of time-independent 
and time-dependent variables on overall survival.  
Results:   Mean overall survival was 18.85 months (median 14, range: 1-148). The 
analysis of time-independent Cox models revealed that portal vein thrombosis (HR= 
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2.47, 95% CI= 1.32-4.64, p=0.01) and uni-dimensional tumor size greater than 5 cm (5-
7.99 cm, HR= 3.16, 95% CI=1.27-7.90, p=0.01; 8-11.99 cm, HR=3.37, 95% CI=1.37-
8.30, p=0.01; >12 cm, HR=3.56, 95% CI= 2.46-22.53, p<0.0001) were independent 
baseline predictors of decreased overall survival, after adjusting for ethnicity and etiology 
of cirrhosis. The analysis of time-dependent Cox models revealed that an ECOG status of 
1 or 2 (adjusted HR=1.83, 95% CI=1.11-3.03, p=0.02,) and a CTP score of B (adjusted 
HR=1.50, 95% CI=1.07-2.12, p=0.02), were independent time-varying predictors of 
decreased overall survival. 
Conclusion: The results of our statistical analyses using time-dependent variables 
highlights the prognostic value of longitudinally collected markers and should alert 
clinicians to the value of their collection and assessment.  
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CHAPTER 1. INTRODUCTION 
 
In clinical oncologic research studies, repeatedly or longitudinally measured disease 
imaging and biological markers are used to monitor treatment and disease progression. 
Analysis of longitudinal data, such as clinical and/or radiologic metrics of response to 
therapy, biochemical and/or genetic biomarkers, or health-related quality of life 
outcomes, may aid in predicting a time to event, such as relapse-free survival or overall 
survival. Longitudinal studies are becoming increasingly used, since they may provide a 
better and growing understanding of the risk of death in patients who are repeatedly 
evaluated over time. 
The goal of this work is to present and investigate methods for assessing the 
association between repeatedly measured clinical and imaging markers of disease control 
and overall survival in patients with unresectable hepatocellular carcinoma (HCC) who 
are treated with transcatheter arterial chemoembolization (TACE). Our study hypothesis 
is that longitudinally measured tumor imaging and clinical data in such patients are 
superior predictors of overall survival than imaging and clinical data collected at 
baseline. To test our hypothesis, we will examine prospectively collected imaging and 
clinical data from patients with unresectable HCC treated with TACE. TACE is an 
established treatment for patients with unresectable HCC and is commonly administered 
more than once in each patient. The physician decision to retreat is based on a 
combination of endogenous parameters, such as the degree of liver function deterioration 
together with the degree of tumor response to therapy, for each patient. Although TACE 
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is a locally targeted therapy, some non-targeted chemotherapy deposition in the 
surrounding hepatic parenchyma occurs and further deteriorates an already compromised 
liver function. Because HCC very often appears in patients already having a cirrhotic 
liver background, it is important to describe patients’ changes in liver function and tumor 
response to therapy over time.  
The primary purpose of this work is to determine whether baseline and longitudinal 
estimates of tumor response to therapy and liver function scores are predictive of overall 
survival in patients with unresectable HCC treated with TACE. The outline of this work 
is as follows. Chapter 2 presents background information describing the epidemiology 
and diagnosis of HCC, the TACE procedure and the current evidence of effectiveness and 
efficacy in patients with unresectable HCC, the imaging criteria for evaluating tumor 
response to therapy and the classification system for evaluating liver cirrhosis. Chapter 3 
presents a description of the methods used for evaluating longitudinal and survival data. 
Chapter 4 presents the results of the statistical analyses obtained using the Johns Hopkins 
Hospital HCC TACE database. Finally, in Chapters 5 and 6, respectively, conclusions are 
presented and future directions are discussed. 
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CHAPTER 2. BACKGROUND 
2.1.  Epidemiology And Diagnosis Of Hepatocellular Carcinoma 
Each year, hepatocellular carcinoma (HCC) is diagnosed in more than 500,000 
people worldwide, with approximately 20,000 new cases in the United States, where 
HCC is the fastest growing cause of cancer-related death (Hashem B. El-Serag, 2011; H. 
B. El-Serag & Davila, 2011). HCC incidence rates are increasing in the United States and 
many other parts of the world, not only due to improved surveillance methods, but also 
possibly due to the obesity epidemic and the rise in HCV infection (Davis, Alter, El-
Serag, Poynard, & Jennings, 2010; Hashem B. El-Serag, 2011; Jemal et al., 2011). Other 
notable risk factors for the development of HCC, such as HBV infection and lack of 
immunization against HBV or alcoholic cirrhosis may also contribute to the increase of 
HCC incidence rates. Notably, unlike most other solid cancers, prevalence and mortality 
rates for HCC are projected to increase over the next 20 years (Davis et al., 2010).   
The diagnosis of HCC is based on the results of typical radiological features in at 
least two imaging modalities including ultrasound, magnetic resonance imaging (MRI), 
contrast-enhanced dynamic computed tomography (CT), and hepatic arterial 
angiography, or by a single positive imaging technique accompanied with serum α-
fetoprotein (AFP) level >400 ng/mL or by histology(Bruix et al., 2001). Despite the fact 
that improved methods of surveillance utilization have increased the number of patients 
with HCC at earlier stages of disease progression, most patients with HCC already have 
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advanced and unresectable disease at the time of diagnosis and are being thus offered 
only non-surgical treatment options (H. B. El-Serag & Davila, 2011; Liapi & Geschwind, 
2007, 2010a, 2010b; B. H. Zhang, Yang, & Tang, 2004). Additionally, almost 80% of 
patients with unresectable HCC have underlying liver cirrhosis(H. B. El-Serag & 
Rudolph, 2007; D. Poon et al., 2009). This results in a degree of complexity that is not 
present in some other cancer types, making optimal treatment choice a challenge. 
2.2. Transcatheter Arterial Chemoembolization For Treatment Of 
Unresectable Hepatocellular Carcinoma 
Among non-palliative treatment options for patients with unresectable HCC, intra-
arterial therapies offer targeted anti-cancer therapy with local intra-arterial hepatic 
injection, using x-ray image-guidance (Liapi & Geschwind, 2007). The most commonly 
performed intra-arterial therapies include transcatheter arterial chemoembolization 
(TACE) with ethiodized oil, transcatheter arterial chemoembolization with drug-eluting 
beads (DEB-TACE), hepatic arterial embolization (HAE) and radioembolization (RE) 
(Lewandowski, Geschwind, Liapi, & Salem, 2011; Liapi & Geschwind, 2007, 2010a, 
2010b, 2011). TACE is currently the most widely performed therapy throughout the 
world and is the focus of the current work. 
Transcatheter arterial chemoembolization (TACE) with ethiodized oil (or lipiodol) for 
treatment of unresectable HCC was originally introduced in the 1980s (Yamada et al., 
1980; Yamada et al., 1983). TACE involves the local intra-arterial hepatic injection of 
one or more chemotherapeutic agents along with ethiodized oil and embolic materials. 
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The chemotherapy (commonly doxorubicin or cisplatin) is suspended in ethiodized oil 
(an oily contrast medium selectively retained within tumors) and injected via a catheter 
into the hepatic arteries that directly supply the tumor. The tumor feeding arteries are 
subsequently infused with embolic materials, most commonly microspheres, so as to 
decrease blood flow to the tumor and allow prolonged retention of chemotherapy to the 
tumor (Liapi & Geschwind, 2007, 2010a, 2010b, 2011; Liapi, Lee, Georgiades, Hong, & 
Geschwind, 2007).  
Almost fifteen years ago, two randomized controlled trials (RCT) demonstrated a 
significant survival benefit in patients with unresectable HCC undergoing TACE versus 
best supportive care (Llovet et al., 2002; Lo et al., 2002). Since then, TACE has been 
considered as the standard of care in patients with unresectable HCC(Basile, Carrafiello, 
Ierardi, Tsetis, & Brountzos, 2012). In these two RCT studies, however, TACE was 
compared against best supportive care in selected patients with well-preserved liver 
function (Llovet et al., 2002; Lo et al., 2002).  Moreover, different chemotherapeutic 
agents and embolic materials were used in each of these studies. Since then, several 
observational cohort studies and case series have shown the efficacy of TACE (Liapi & 
Geschwind, 2007, 2010a, 2010b, 2011; Takayasu et al., 2006). Meta-analyses and 
systematic reviews, however, have demonstrated conflicting findings regarding the 
benefit of TACE, thus far (Forner, Llovet, & Bruix, 2012; R. S. Oliveri, Wetterslev, & 
Gluud, 2011; Roberto S. Oliveri, Wetterslev, & Gluud, 2012). Under the umbrella of the 
TACE procedure, investigators may often include procedures that do not require injection 
of chemotherapy, such as the procedure of lipiodolization or the procedure of hepatic 
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arterial embolization (HAE). It has been argued, however, that tumor ischemia alone, 
induced by these procedures may not lead to tumor death (Rose et al., 2013). Whereas an 
initial meta-analysis demonstrated a survival benefit for patients treated with TACE over 
best supportive care, a more recent one could not support evidence that either TACE or 
hepatic arterial embolization (HAE) has a beneficial effect on survival in patients with 
unresectable HCC (Forner et al., 2012; Llovet & Bruix, 2003; R. S. Oliveri et al., 2011; 
Roberto S. Oliveri et al., 2012). This could be attributed to the introduction of new 
variations of the TACE procedure, such as the DEB-TACE, or variations in the 
chemotherapy and embolization protocols. 
 
2.3. Child-Turcotte-Pugh Classification Method of Liver Cirrhosis 
Severity 
Liver cirrhosis is the final common histologic pathway for a wide variety of chronic 
liver diseases, such as alcoholic liver disease, or hepatitis C (Heidelbaugh & Bruderly, 
2006). Liver cirrhosis is a severe condition for which overall survival is the principal 
endpoint (Durand & Valla, 2005). In addition, HCC occurs in the setting of liver cirrhosis 
in up to 80% of patients (H. B. El-Serag & Davila, 2011; H. B. El-Serag & Rudolph, 
2007; D. Poon et al., 2009).  
The most commonly used method to classify patients according to the extent of 
liver cirrhosis is the Child-Turcotte -Pugh (CTP) classification (Pugh, Murray-Lyon, 
Dawson, Pietroni, & Williams, 1973). This classification provides a simple method for 
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identifying patients at risk for liver insufficiency. Child and Turcotte initially developed 
this classification in 1964 and Pugh modified this in 1973 (Child & Turcotte, 1964; 
Durand & Valla, 2005; Pugh et al., 1973). The current CTP scoring system is based upon 
five parameters: serum bilirubin, serum albumin, prothrombin time, ascites and 
encephalopathy. The total score, corresponding to the sum of individual points across the 
five parameters (Table 1), allows categorizing patients by CTP grades A (5-6 points), B 
(7-9 points) and C (10-15 points).  Of note, the total range of points (5-15) is not equally 
distributed among grades A, B and C, signifying the additive clinical impact of the each 
grade in terms of prognosis. These grades have been shown to correlate with the 
following one and two- year survival rates: Grade A, 100% and 65%; Grade B, 80% and 
60%; and Grade C, 45% and 35%, respectively (Durand & Valla, 2005, 2008). A recent 
systematic review found that the median survival was ≤6 months in patients with 
cirrhosis CTP score ≥12 (Salpeter, Luo, Malter, & Stuart, 2012). 
Table 1. Child-Turcotte-Pugh (CTP) classification of liver cirrhosis severity. The total 
score, corresponding to the sum of individual points across the five parameters, allows 
categorizing patients by CTP grades A (5-6 points), B (7-9 points) and C (10-15 points). 
Parameter Points Assigned 
1 2 3 
Ascites Absent Slight Moderate 
Bilirubin (mg/dL) <2 2 to 3 >3 
Albumin (g/dL) > 3.5 2.8 to 3.5 < 2.8 
Prothrombin Time  
Seconds prolonged 
1 to 3 4 to 6 >6 
INR < 1.7 1.8 to 2.3 > 2.3 
Encephalopathy None Minimal  Advanced 
INR: International Normalized Ratio. Prothrombin time values of 4 and 6 seconds correspond 
approximately to 50% and 40% of normal, respectively. Either Prothrombin Time or INR is used for 
calculating the final score. 
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The original score was initially proposed in the limited setting of the evaluation of 
surgery for portal hypertension (Child & Turcotte, 1964). Subsequently, its prognostic 
value was demonstrated in the settings of ascites (Merkel et al., 2000), variceal bleeding 
(Fernandez-Esparrach et al., 2001), subclinical encephalopathy (Hartmann et al., 2000), 
small untreated HCC (Barbara et al., 1992), abdominal surgery (Mansour, Watson, 
Shayani, & Pickleman, 1997), alcoholic cirrhosis (Gluud, Henriksen, & Nielsen, 1988), 
decompensated HCV-related cirrhosis (Planas et al., 2004),  primary sclerosing 
cholangitis (Shetty, Rybicki, & Carey, 1997),  primary biliary cirrhosis (van Dam et al., 
1999) and Budd-Chiari syndrome (Zeitoun et al., 1999). 
The CTP score has not been rigorously validated in patients treated with intra-
arterial therapies. However, decompensated liver cirrhosis (CTP class C with numeric 
score > 12) has long been considered to be a contraindication to the intra-arterial 
approach, not only because of the possibility of severe complications following the 
procedure but also due to the poor prognosis despite treatment in such patients (Liapi, 
Georgiades, Hong, & Geschwind, 2007). Surprisingly, the effect of intra-arterial 
therapies on the cirrhotic liver has not been reported very extensively (Adhoute, 
Penaranda, Castellani, Perrier, & Bourliere, 2015; Ogasawara et al., 2015). In the case of 
TACE in patients with cirrhosis, few authors have reported on the effect of the procedure 
on liver function and the damage caused by TACE to non-tumorous liver tissue (Khan et 
al., 1991). 
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2.4.  Radiologic Evaluation of Hepatocellular Carcinoma Response To 
TACE 
Imaging quantification methods for evaluating the treatment response of liver 
tumors to transcatheter arterial therapies, including TACE, provide treating physicians 
with an insight of the effect of chemotherapy and embolization on disease progression. 
Current size-based criteria for assessing cancer response to therapy include the World 
Health Organization (WHO) criteria and the Response Evaluation Criteria in Solid 
Tumors (RECIST) (Eisenhauer et al., 2009; Miller, Hoogstraten, Staquet, & Winkler, 
1981).  
The WHO criteria were the first criteria established for the recording and reporting 
of solid tumor response to therapy, in 1979 (Miller et al., 1981). These criteria attempted 
to standardize the recording and reporting of response assessment for solid tumors, so as 
to allow comparisons between research studies throughout the world. Assessment of 
tumor response according to  the WHO criteria is performed by measuring the product of 
the longest axial diameter and greatest perpendicular diameters for each tumor.  
Complete response (CR) is defined as the disappearance of all signs of disease for at least 
1 month and the lack of appearance of new lesions. Partial response (PR) is achieved with 
a 50% or more reduction in the sum of the tumor cross product sizes. Stable disease (SD) 
indicates a decrease of <50% or an increase in tumor size of <25% over the original 
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measurements. Progressive disease (PD) is considered a 25% or more increase in the sum 
of one or more of the tumor measurements or the appearance of new lesions. 
In 1994, several organizations, including the European Organization for Research 
and Treatment of Cancer, the National Cancer Institute of USA and the National Cancer 
Institute of Canada began to review the response assessment criteria with the intent of 
revising them. The revised system, the Response Evaluation Criteria In Solid Tumors 
(RECIST), used the longest only axial tumor diameter (uni-dimensional) for each tumor 
(and up to 5 tumors per target organ), which are less cumbersome to measure and 
calculate (Therasse et al., 2000). The revised RECIST version 1.1 guidelines were 
established in 2009 and use uni-dimensional tumor measurements of up to two target 
lesions per organ (Eisenhauer et al., 2009). A sum of the longest diameter for these two 
target lesions is calculated and reported as the baseline sum of the longest diameters. To 
characterize the objective tumor response, the baseline sum of the longest diameters is 
used as the reference. Complete response (CR) is disappearance of all known lesion(s) 
confirmed at 4 weeks. Partial response (PR) is 30% or more decrease in the sum of the 
longest diameters confirmed at 4 weeks. Stable disease (SD) is when neither PR nor PD 
criteria are met. Progressive disease (PD) is 20% or more increase in the sum of the 
longest diameters and an absolute increase of 5 mm for each target lesion or appearance 
of new lesion(s). Lymph nodes are considered a measurable and possible target lesion if 
they measure more than 15 mm in the short axis. 
The relevance of the application of the RECIST criteria to TACE has been 
challenged, since TACE may lead to tumor ischemia and necrosis that may not always be 
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paraleled by a reduction in size (Bruix et al., 2001; Lencioni & Llovet, 2010). More 
recently the American Association for the Study of Liver Diseases (AASLD) has 
proposed a formal amendment of the RECIST criteria to take into consideration changes 
in the degree of tumor arterial enhancement – the modified RECIST criteria (mRECIST) 
(Lencioni & Llovet, 2010). According to the mRECIST, the following RECIST 
modifications were proposed in the determination of tumor response for target lesions:  
CR is considered the disappearance of any intratumoral arterial enhancement in all target 
lesions. PR is considered at least a 30% decrease in the sum of longest diameters of 
viable (contrast enhancement in the arterial phase) target lesions, taking as reference the 
baseine sum of the longest diameters of target lesions. PD is characterized as an increase 
of at least 20% in the sum of the diameters of viable (enhancing) target lesions, taking as 
reference the smallest sum of the longest diameters of viable (enhancing) target lesions 
recorded since the treatment started. SD includes any cases that do not qualify for either 
PR or PD (Table 2). 
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Table 2. Radiologic Imaging criteria for evaluating tumor response to therapy: 
comparison of the RECIST v.1.1 and mRECIST.  
 RECIST mRECIST* 
CR Disappearance of all target 
lesions 
Disappearance of any intratumoral arterial 
enhancement in all target lesions 
PR At least a 30% decrease in the 
sum of longest diameters of 
target lesions, having as 
reference the baseline sum of 
the longest diameters of target 
lesions 
At least a 30% decrease in the sum of longest 
diameters of viable (enhancement in the 
arterial phase) target lesions, having as 
reference the baseline sum of the longest 
diameters of target lesions 
SD Any cases that do not qualify 
for either partial response or 
progressive disease 
Any cases that do not qualify for either partial 
response or progressive disease 
PD An increase of at least 20% in 
the sum of the longest diam-
ters of target lesions, having 
as reference the smallest sum 
of the longest diameters of 
target lesions recorded since 
treatment started 
An increase of at least 20% in the sum of the 
diameters of viable (enhancing) target lesions, 
having as reference the smallest sum of the 
longest diameters of viable (enhancing) target 
lesions recorded since treatment started 
*Adapted from Lencioni R, Llovet JM(Lencioni & Llovet, 2010). Abbreviations: mRECIST, modified 
Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable 
disease; PD, progressive disease. 
 
Currently, there is little evidence whether longitudinally measured RECIST and 
mRECIST scores are superior in predicting HCC patients’ overall survival, compared to 
metrics obtained at baseline. Our hypothesis is that longitudinally measured tumor 
imaging and clinical biomarkers of liver function are superior predictors of OS than 
biomarkers measured at baseline. 
 
 
	   	  13 
2.5. Patient Performance Status  
Several patient performance status instruments are available to clinicians for 
evaluating patient performance status. In oncology, the most commonly used are the 
Karnofsky Performance Scale and the Eastern Cooperative Oncology Group (ECOG) 
scale.  
The Karnofsky Performance Scale was developed in the 1980s as an attempt to 
measure the more subjective aspects of the outcome of cancer treatment (Mor, Laliberte, 
Morris, & Wiemann, 1984). The scale only relates to the physical ability. It quickly and 
easily indicates how the patient is feeling on a given day. The Karnofsky Performance 
Scale covers 11 points, from normal health to death. Each is scored from 0 to 100. 
The performance status scale developed by the Eastern Cooperative Oncology Group 
(ECOG) was developed in the1980s as an attempt to measure the more subjective aspects 
of the outcome of cancer treatment(Oken et al., 1982).The ECOG scale records activity 
on a scale from 0 (fully active, able to carry on all pre-disease performance without 
restriction) to 5 (dead). Table 3 provides a description of scoring values of the ECOG 
performance status scale. Physicians routinely use these criteria and scales to evaluate the 
progression of cancer and how the daily living ability of patients is affected. In addition, 
performance status is used as an indicator of treatment and predictor of long-term 
survival. However, few studies have specifically investigated the influence or prognostic 
ability of performance status on HCC patients (Hsu et al., 2013; Nishikawa et al., 2015). 
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Table 3. Description of scoring values of the ECOG performance status scale (Oken et 
al., 1982). 
Score Description 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry 
out work of a light or sedentary nature, e.g., light house work, office work 
2 Ambulatory and capable of all self care but unable to carry out any work 
activities; up and about more than 50% of waking hours 
3 Capable of only limited self care, confined to bed or chair for more than 50% 
of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed 
or chair 
5 Dead 
2.6  Specific Aims 
Because the relationship between overall survival (OS) and longitudinal measures 
of radiologic tumor response and liver function deterioration after TACE have not been 
extensively studied in patients with unresectable HCC, we sought to determine whether 
any of these repeatedly obtained measurements can predict OS in a single center 
prospective study.   Our study hypothesis is that longitudinally measured tumor imaging 
and clinical variables of clinical performance and liver function are superior predictors of 
OS than variables measured at baseline. To test our hypothesis, we examined 
prospectively collected tumor imaging and clinical liver function data from patients with 
unresectable HCC treated with TACE and sought to:  
Specific Aim 1: Evaluate whether baseline patient characteristics could predict 
overall survival.  
Specific Aim 2: Evaluate whether longitudinally obtained measurements with 
time-varying covariates could predict patient overall survival. 
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CHAPTER 3. METHODS 
3.1  Study Design 
This study is a HIPAA-compliant, IRB-approved single center observational study 
of consecutive patients with unresectable HCC treated at the Johns Hopkins Hospital 
(JHH) with TACE, between January 2001 and November 2008. Data were retrieved from 
JHH electronic patient records.  
Inclusion criteria were: diagnosis of hepatocellular carcinoma (HCC) according to 
imaging and/or laboratory criteria, treatment with TACE between 1/1/2001 and 
11/28/2008, at least one imaging study of the liver, at least one laboratory biochemical 
evaluation of the liver with clinical evaluation of ascites and encephalopathy. Exclusion 
criteria were:  treatment with any other intra-arterial therapy other than TACE (such as 
drug-eluting beads TACE, radioembolization, or hepatic arterial embolization), before, 
during and at the end of the study period. Patients receiving transplantation or had 
recurrent disease were excluded from the study. Patients treated with previous TACE 
sessions outside the JHH were excluded from the study. Patients who had previously 
received systemic chemotherapy, surgery, ethanol or radiofrequency ablation, were also 
excluded from the analysis. For the longitudinal data analysis, patients included in the 
study had to have baseline and last follow-up (exit) imaging and liver function tests. 
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Therefore, patients without baseline and/or exit information on their CTP score, RECIST 
and mRECIST scores were subsequently excluded from the study.  
Administrative censoring occurred at the study end date (11/28/2008). A total of 
211 patients were initially eligible. A total of 92 patients were excluded, as they did not 
fulfill the repeated measures study entry criteria. Thus, 119 patients were included in the 
repeated measures analysis. The patients were observed until either the primary endpoint 
(death) or administrative censoring (11/28/2008) occurred. Vital status information was 
obtained on patients via a private Social Security Death Index Registry. Figure 1 shows a 





Figure 1. Flow chart of patients with unresectable HCC treated with TACE at the JHH 
between 2001 and 2008. Patients could be excluded for multiple reasons. 
3.2  Johns Hopkins Hospital TACE Treatment and Follow-up 
Protocol  
The Johns Hopkins Hospital TACE treatment protocol consists of selective or 
supraselective TACE with use of 50 mg doxorubicin, 100 mg cisplatin and 10 mg of 
mytomicin C mixed with ethiodized oil, followed by the injection of embolic 
microspheres. The procedural steps can be summarized as follows: 
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The single-wall Seldinger technique with an 18-gauge needle is used to access the 
right common femoral artery. A 5-French vascular sheath is then placed into the artery 
over a 0.035 glide wire. Under fluoroscopic guidance, a 5-French catheter is then used to 
select the superior mesenteric artery (SMA) and the celiac axis. The SMA angiography is 
essential to identify variant and hepatic accessory arteries, retrograde flow though the 
gastroduodenal artery (GDA), and visualize portal vein patency. Over the guide wire, the 
5-French catheter is next advanced into the desired hepatic artery branch, depending on 
tumor location. TACE is then performed with supraselective catheterization of the 
hepatic arteries that feed a tumor and intra-arterial injection of a solution containing 
cisplatin 100 mg, doxorubicin 50 mg and mitomycin C 10 mg in a 1:1-2:1 mixture with 
ethiodized oil. This is followed by injection of 3-6 ml of a mixture containing embolic 
microspheres (100–300 µm in size) suspended in 1:1 ratio of contrast medium. The 
technical endpoint of TACE is successful delivery of chemotherapy with targeted 
ethiodized oil deposition, reduction of arterial inflow to the tumor and tumor de-
vascularization (Liapi, Georgiades, et al., 2007).  
The JHH TACE evaluation and follow-up protocol includes: a) a baseline clinical 
visit, during which baseline imaging, clinical evaluation and liver function tests were 
obtained, b) TACE treatment, c) first follow-up visit, 4-6 weeks after first TACE, during 
which imaging, clinical evaluation and liver function tests were obtained. A subsequent 
TACE session was performed, only if all of the following conditions were met: a) 
presence of persistent untreated disease, indicated by imaging, b) adequate liver function, 
indicated by liver function tests that did not show CTP score C, c) absence of post-
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operative complications, such as liver abscess, d) patient’s agreement to continue therapy. 
Patients with no remaining untreated disease were closely observed with imaging and 
liver function tests every 4- 6 weeks and until recurrent untreated disease occurred. The 
2nd follow-up visit occurred, either 4-6 weeks after the second TACE, or 2-3 months after 
the first TACE. Similarly, the 3rd follow-up visit occurred, either 4-6 weeks after the third 
TACE session, or 4-6 months after the first TACE session. Subsequent sessions occurred 
at unpredictable intervals, based on the endogenous algorithm assessment of each 
biochemical and imaging follow-up, which occurred every 4-6 weeks, irrespectively of 
therapy. For simplicity purposes, we consider each visit as a landmark time point and the 
last follow-up visit was the last before study exit.  
3.3  Imaging Protocol 
All radiological assessment was performed using magnetic resonance imaging 
(MRI). The MRI protocol included gradient echo T1-weighted (T1 GRE) fat suppressed 
sequences before and after intravenous injection of gadolinium (Gd) agent, turbo spin-
echo T2-weighted (T2 TSE) sequences (Kamel et al., 2009; Kamel, Reyes, Liapi, 
Bluemke, & Geschwind, 2007).  
All treated lesions were measured on the arterial phase of post-Gd T1 GRE 
dynamic sequences according to: a) RECIST criteria, by measuring the percentage of 
change in the sum of the maximal bi-dimensional perpendicular diameters and the 
maximal uni-dimensional diameter, including viable and non-enhancing areas within the 
tumor, and b) mRECIST criteria, by measuring the percentage of change in the sum of 
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the maximal bi-dimensional diameters and the maximal uni-dimensional diameter, 
including only the enhancing portion of the tumor. For these response criteria, radiologic 
interpretation was classified as complete response (CR), partial response (PR), stable 
disease (SD), or progressive disease (PD) according to cutoffs defined in Chapter 2. 
Measurements were repeated at each follow-up visit until study exit.  
3.4  Study Variables  
In this study, we prospectively collected time-independent (baseline) and time-dependent 
(repeatedly measured) variables. Table 4 shows the baseline variables: age at study entry, 
gender, ethnicity, etiology of hepatic cirrhosis, presence of extrahepatic metastases and 
baseline clinical performance status.  
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Table 4.Time-independent baseline covariates, measured at baseline only, of patients 








Age Continuous Age in years, 
calculated at the 
time of baseline 









Ethnicity Categorical Ethnicity 
 
White=0  
African American=1  








Hepatitis-B related cirrhosis=1,  
Hepatitis-C related cirrhosis=2,  
Alcoholic cirrhosis=3,  
Combination of HBV and HCV-
related cirrhosis=4,  
Combination of alcoholic and 
HBV=5,  
Combination of alcoholic and 
HCV=6,  
Combination of alcoholic and 
HBV/HCV=7 
Hemochromatosis=8,  
Hemochromatosis and HBV=9,  
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Repeatedly measured variables, were measured longitudinally, at baseline, 1st, 2nd 
and last recorded visits, and included imaging and biochemical variables, as listed in 
Table 5. Imaging variables included the longest axial tumor size, tumor response by 
RECIST and mRECIST, presence of portal vein thrombosis, presence of untreated 
tumor(s), and tumor burden. All measurements were taken from computed tomography or 
magnetic resonance imaging scans interpreted by at least one JHH staff radiologist. 
Biochemical parameters included the numerical and categorical CTP scores, as well as 
the individual variables that comprise these scores (albumin, bilirubin, prothrombin time, 
ascites, and encephalopathy). 
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Table 6. Repeatedly measured covariates of patients with unresectable HCC treated with 
















Categorical  Categorical CTP score,  A (5-6 points)=1 
B (7-9 points)=2 




Continuous Longest unidimensional 
axial tumor diameter, 
measured in centimeters 
(cm) 
 
RECIST Ordinal Tumor response to therapy 




Partial Response (PR)=1  
Stable Disease (SD)=2 
Progressive Disease 
(PD)=3 
mRECIST Ordinal Tumor response to therapy 






Partial Response (PR)=1  
Stable Disease (SD)=2 
Progressive Disease 
(PD)=3 
PVT Binary Portal vein thrombosis of 
the main or any segmental 





Binary Presence of non-targeted 
tumors, as recorded on 






Categorical Tumor burden, described 
as the total number of 
tumors 
Single tumor=1 
Two or three tumors=2 
More than three tumors=3 
Extrahepatic 
Disease 
Categorical Presence of extrahepatic 
disease 
No=0 
Regional lymph nodes=1 
Distant metastases=2 
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* CTP scores, presence of PVT, extrahepatic metastases, tumor burden, were measured at 
baseline, first follow-up, second follow-up and last visit. RECIST, mRECIST scores and presence 
of untreated disease were recorded at first follow-up, second follow-up and last visit. 
3.5  Study Endpoint 
The primary outcome of this study was overall survival (OS) and was measured in 
months from baseline imaging assessment until either death, or at the time point at which 
there was loss to follow-up or administrative censoring.  
3.6  Statistical Methods 
Statistical analysis included both exploratory data analyses and survival analysis 
utilizing time-independent and time-dependent variables.  
3.6.1  Exploratory Data Analysis 
Exploratory data analysis (EDA) aided in study hypothesis building and included 
non-graphical and graphical methods of data analysis. Univariate EDA included 
summary statistics of each continuous variable with respect to central tendency (mean, 
median), spread (standard deviation, variance, interquartile range), shape (skewness, 
kurtosis) and outliers. Distributions of continuous variables were explored using dot 
plots, box plots, and quantile-normal plots.  Distributions of categorical variables were 
explored using frequency distributions. 
 Bivariate associations were inspected visually through side-by-side box plots, 
two-way plots and scatterplots, and cross-tabulations. Bivariate analysis were performed 
using Mann Whitney's U test, the Student t test, chi-square test, or Fischer's exact test, as 
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appropriate, to compare baseline characteristics between excluded and included patients. 
Comparisons of baseline characteristics between these two groups were performed for the 
following variables: a) age (with the Wilcoxon rank-sum test), b) gender, c) ethnicity, d) 
type of hepatic cirrhosis, e) ECOG patient performance status, f) presence of extrahepatic 
disease, g) tumor size, h) CTP score and i) portal vein thrombosis, using the Pearson’s 
chi-squared test. Comparisons for detecting differences in baseline tumor size 
measurements among the three baseline RECIST categories and the four baseline 
mRECIST categories were performed suing Kruskal-Wallis H-test. Scatter graphics 
representing the percentage of change in longest axial tumor size at each visit were built 
and spaghetti plots of RECIST, RECIST, and categorical CTP measurements were 
constructed, considering all follow-up visits until study exit. Box and whisker box plots 
showing median, range, and interquartile values, were constructed to investigate changes 
between baseline and the 1st, 2nd and last visits, in RECIST, mRECIST, and CTP scores, 
visually as well as with Friedman's two-tailed test and Wilcoxon's test. Tumor 
radiological response and liver function classification were represented by summary 
statistics and graphical methods. For all tests, a P value <0.05 was considered statistically 
significant. All analyses were conducted using STATA 12 software (StataCorp. 2011. 
Stata Statistical Software: Release 12. College Station, TX: StataCorp LP). 
3.6.2  Kaplan-Meier Survival Analysis  
Kaplan-Meier estimates of the cumulative probability of survival were used to 
account for censored and uncensored data. Censored data were defined when the event 
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time of interest was not fully observed on all subjects under study, for instance if they 
were lost to follow up or dropped out of the study, or if the study ended before they died.  
Since survival data were expected to be right skewed, we used rank-based non-
parametric tests followed by estimate and confidence intervals of medians within groups. 
Kaplan-Meier estimates were computed and compared for all baseline characteristics. 
Comparisons between groups were performed using the log-rank test(Kaplan & Meier, 
1958; Mantel, 1966; Peto & Peto, 1972). When comparisons included more than two 
groups, a Bonferroni correction was applied by dividing the assumed significance level 
by the number of comparisons and the log-rank test p-value represented the p-value for 
the trend. 
3.6.3  Multivariable Cox Proportional Hazards Regression Analysis of Baseline 
Covariates 
A univariate Cox regression analysis was first performed to identify baseline 
predictors of the risk of death(Cox, 1972). The Efron approximation was employed for 
tied survival times(Efron, 1977). Characteristics examined at baseline included age, 
gender, ethnicity, type of hepatic cirrhosis, CTP score, ECOG performance status, 
presence of extrahepatic metastases, uni-dimensional longest tumor diameter 
(categorical), tumor burden, as well as portal vein thrombosis. RECIST, mRECIST at the 
first visit were also considered as baseline characteristics and were included in the 
univariate analysis. Predictors were further considered for inclusion in the multivariate 
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proportional hazards regression analysis only if they had achieved a p-value of 
<0.2(Greenland, 1989).  
Covariates were selected for inclusion in the multivariable Cox proportional 
hazards regression model  (Cox, 1972) using stepwise or forward selection methods and 
according to the level of statistical significance as describe above. Caution was taken to 
avoid multi co-linearity by excluding variables that were highly correlated. 
3.6.4  Evaluation of Proportional Hazards Assumption Model for Baseline 
Covariates 
Cox proportional hazard modeling was evaluated for supporting the assumption of 
proportional hazards graphically and by employing the Schoenfeld test.  In order to 
graphically assess the proportional hazards assumption for each model, we generated 
plots of the logarithm of time against the logarithm of the negative logarithm of the 
estimated survivor function for each variable (“log-log” survival curves). For each plot, if 
curves were not crossing each other, then PH assumption was considered to be satisfied.  
For each covariate, the Schoenfeld residuals are defined as the value of 
individuals that failed minus its expected value. We subsequently performed analysis 
of Schoenfeld residuals, by fitting a smooth function of time to the residuals (Schoenfeld, 
1982). If the residual exhibits a random (i.e. unsystematic) pattern at each failure time, 
then this suggests that the covariate effect is not changing with respect to time and the PH 
assumption is met. If it is systematic, it suggests that as time passes, the covariate effect 
is changing.  
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The Schoenfeld test (stphtest) was then used to test the independence between 
residuals and log time(Grambsch & Therneau, 1994). The Schoenfeld test is 
analogous to testing whether the slope of scaled residuals on time is zero or not. If 
the slope is not zero then the proportional hazard assumption has been violated. 
The Schoenfeld test will be performed for each covariate and globally using a formal 
significance test. If a baseline covariate in a model did not meet the proportional hazards 
assumptions, we further stratified models by this covariate. 
3.6.5  Cox Proportional Hazards Regression Analysis using Time-Varying 
Covariates  
In the classical Cox regression model analysis, the prognostic factors represent a 
subject’s condition at the start of the study (e.g. age at baseline, performance status, 
tumour characteristics) and do not change over time. In this study, the biomarkers of 
tumor response and liver function change over time and it is of interest to take this into 
account when modelling overall survival. Therefore, a Cox regression model with time-
dependent covariates was considered (Collet 2003). In this model, the hazard  of death 
is modelled as a function of time , for the -th of  subjects  
 
In this expression  is the baseline hazard function and  represents the value of 
the -th covariate for the -th subject at time . The parameter   
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corresponds to the log hazard ratio for two individuals whose values of  at any time t 
differ by one unit, all other variables being the same at that time. Note that in this model, 
as the values of  may vary over time, the ratio  is also time-dependent 
and the model is no longer a proportional hazards model. The classical Cox regression 
model however follows as a special case where  for all . Furthermore note 
that this model requires the values of the time-dependent covariates to be specified for 
each individual in the risk set at each event time.  
Each study visit was considered as being spaced 2 months apart from a 
subsequent one because this was the assumed time window for follow-up visits. . Panel 
data were set up in the following manner: a) patients that survived less than 1 month were 
excluded from the study, b) patients that survived the 1st visit and died before the end of 
the 2 months period were censored at 1 month, c) patients that survived the 2nd visit and 
died before the end of 4 months period were censored at 3 months, d) patients that 
survived the 3rd visit and died and died before the end of 6 months were censored at 5 
months. In order to perform a complete case analysis, missing values of RECIST, 
mRECIST and CTP scores were dropped from the analysis. 
3.6.6 Model Selection  
When a number of models are fit to the same data set, one method of choosing the 
'best' model is to select the model for which Akaike's information criterion (AIC) is 
lowest (Akaike, 1974). AIC applies when maximum likelihood is used to estimate the 
unknown parameters in the model. The value of -2 log likelihood for each model fit is 
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penalized by adding twice the number of estimated parameters. The number of estimated 
parameters includes both the linear parameters and parameters in the covariance 
structure. Another criterion for model selection is the Bayesian information criterion 
(BIC)(Schwarz, 1978). BIC penalizes -2 log likelihood by adding the number of 
estimated parameters multiplied by the log of the sample size. 
Model selection was performed only for time-independent models. Model 
selection for time-dependent models is considered as future work.
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CHAPTER 4. RESULTS 
4.1. Exploratory Data Analysis 
4.1.1. Patient Demographic Characteristics 
From the total of 211 TACE patients, 119 were included in the longitudinal 
analysis study group and 92 were excluded. The median age in the study group was 61.5 
years (inter-quartile range= 51-69 years, mean=60.45 years, SD=13.34, normally 
distributed with Shapiro-Wilk test p-value=0.70). Most patients were male (83.20%), 
Caucasian (66.90%) and with hepatitis C-related cirrhosis (29.40%). Baseline 
demographic characteristics of patients included in the study, compared to those excluded 
from the study, are shown in Table 6. There were no statistically significant differences 
between the two groups, with respect to age (p=0.32, Wilcoxon rank-sum test), ethnicity 
(p=0.18, Pearson’s chi-squared test) and etiology of hepatic cirrhosis (p=0.59, Pearson’s 
chi-squared test). There was a statistically significant difference in the gender distribution 
(p=0.023, Pearson’s chi-squared test), with a higher proportion of female patients in the 
study group, as compared to those excluded from the study. There was also a statistically 
significant difference in the distribution of patients with extrahepatic metastases 
(p=0.047, Pearson’s chi-squared test), with a higher proportion of patients with enlarged 
regional lymph nodes included in the study. The total numbers of observations for each 
measured variable are shown in Table 7. 
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Table 7. Baseline demographic characteristics of patients with unresectable HCC treated 
with TACE for patients included as compared to patients excluded from the longitudinal 
study.  
 
Factor Included  % Excluded % P-value Test 
N 119  92    
Age, median 
(IQR) 
61        
(51, 69) 
 63            
(53, 71) 
  0.32 Wilcoxon 
rank-sum 
       
Gender     0.023 Pearson's 
chi-squared 
Male 99 83.2 87 93.5   
Female 20 16.8 6 6.5   
       
Ethnicity     0.18 Pearson's 
chi-squared 
White 79 66.9 54 58.1   
African 
American 
22 18.6 23 24.7   
Asian 9 7.6 13 14.0   
Other 8 6.8 3 3.2   
       
Etiology of  
hepatic  
cirrhosis 




34 28.6 32 34.40   
Hepatitis B 23 19.3 11 11.80   
Hepatitis C 35 29.4 31 33.30   
Hepatitis B 
and alcohol 
5 4.2% 4 4.30   
Other* 22 18.5 15 16.10   
       
Baseline 
ECOG Status 
    0.84 Pearson's 
chi-squared 
0 80 67.2 61 65.6   
1 or 2 39 32.8 28 30.1   






   0.047 Pearson's 
chi-squared 
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None 91 76.50 82 88.20%   
Regional 
lymph nodes 
14 11.80 3 3.20   
Distant 
metastases 
14 11.80 8 8.60   








2-4.99  24 26 27 41   
5-7.99  24 26 20 30   
8-11.99  32 34 13 20   
12-16 14 15 6 9   
       
Baseline  
CTP score 
    0.25 Pearson's 
chi-squared 
A 80 67.20 56 70.90   
B 36 30.30 18 22.80   
C 3 2.50 5 6.30   
       
Baseline  








 0.65 Pearson's 
chi-squared 
No 89 74.80 67 72.00   
Yes 30 25.20 26 28.00   
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none 
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Table 8. Total number of observations for each measured variable for patients included 
and excluded from the study. Parentheses indicate the percent missing data for each 
measured variable. 
 Included 







 N=119  N=92  
Age  118  0.8 92 0 
Gender 119 0 92 0 
Ethnicity 118  0.8 92 0 
Hepatic cirrhosis 119 0 92 0 
Baseline ECOG 
status 
119 0 92 0 
Metastases 119 0 92 0 
Baseline CPT score 119  0 92 0 
Baseline tumor size 94  21 66 28.3 
Baseline PVT 118 0.8 92 0 
1st RECIST score  119 0 47  48.9 
1st mRECIST score 119 0 47 48.9 
1st CPT score  99 16.8 24 73.9 
2nd RECIST  118  0.8 53 42.4 
2nd mRECIST 118 0.8 53 42.4 
2nd CPT score  100 16 24 73.9 
Last RECIST  119 0 56 39.1 
Last mRECIST  119 0 56  39.1 
Last CTP score 119 0 25 72.8 
 
Missing data for patients included in the study were less than 10% for each measured 
variable, with the exception of baseline tumor size (21%) and CTP score at 1st follow-up 
visit (16.8%) and CTP score at 2nd follow-up visit (16%).  
The median number of TACE sessions per patient was 2 (mean=2.64, SD=1.63 
sessions). Most patients (39.5%) received 2 TACE sessions, where as 15.6% received 3 




Figure 2. Distribution of the number of TACE sessions per patient. 
 
 The baseline mean uni-dimensional longest tumor diameter was 7.76 cm 
(SD=3.62 cm, median=7.5cm, inter-quartile range=4.7-10 cm; not normally distributed 
by Shapiro-Wilk test, p-value=0.01). Figure 3 shows the distribution of baseline uni-
dimensional tumor size by baseline CTP score (Kolmogorov-Smirnov test for equality of 
distribution functions, p=0.92). Figure 4 shows the distribution of baseline uni-
dimensional tumor size by gender. Figure 5 shows the distribution of baseline uni-
dimensional tumor size by 1st RECIST tumor response. No statistically significant 
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differences for baseline uni-dimensional tumor size measurements were observed among 
the three baseline RECIST categories (Kruskal-Wallis H-test p-value: 0.80). 
 
Figure 3. Distribution of baseline uni-dimensional tumor size (in cm) across patients 




Figure 4. Distribution of baseline uni-dimensional tumor size (in cm) across patients 





Figure 5. Box and whisker plots of baseline uni-dimensional tumor size (cm) by baseline 
RECIST categories (p=0.80, Kruskal-Wallis test). PR=partial response, SD= stable 
disease, PD=progressive disease. 
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4.2. Analysis of Trends Over Time 
4.2.1. Assessment Of Liver Function Over Time 
 Our study population consisted of 119 patients that had primarily a baseline CTP 
score of A (n=80), while 36 had CTP score B and 3 had advanced liver cirrhosis (CTP 
score C). After the first TACE session, patients were re-evaluated in a subsequent visit 
(1st follow-up visit) with calculation of the numeric and categorical CTP score. Either 
after the 2nd TACE session or after 4-6 weeks from the 1st visit, patients were asked to 
follow up with a subsequent visit (2nd visit). The last visit was the last visit prior to study 
exit and varied for each patient. At the 1st follow-up visit, 60 patients had a CTP A score, 
32 had CTP B score and 7 had a CTP score of C, with 20 missing values. At the 2nd 
follow-up visit, 60 patients had a CTP score of A, 28 had CTP B score and 9 had a CTP 
score C, with 19 missing values. At the final visit, 58 patients had a CTP score of A, 59 
had CTP score of B and 16 had a CTP score of C. Table 8 demonstrates the number of 
patients and categorical CTP scores at each visit, as well as the total count of each CTP 
score and the percent change in the counts of each score compared to baseline. At the 
final visit, there was a 32.5% decrease in CTP score A, a 44.5% increase in CTP score B 
and a 333% increase in CTP score C. Figure 6 shows a spaghetti plot of the CTP 
predicted values using a linear regression model of observed CTP score on visit for each 
patient. 
According to the numerical CTP score, patients had a baseline mean numerical 
CTP score of 6.17 (SD=1.52, range: 4-13). On the 1st follow-up visit, the mean numerical 
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CTP score was 6.43 (SD=1.60, range: 3-11, p=0.233, compared to baseline), on the 2nd 
follow-up visit the mean score was 6.66 (SD=1.68, range: 5-12, p=0.025 compared to 
baseline) and on the last follow-up the mean CTP score was 7.10 (SD=1.79, range: 5-12, 
p<0.00001 compared to baseline CTP score. Although there is a statistically significant 
difference between the 2nd and baseline CTP scores, as well as the last and baseline CTP 
scores, mean numerical values for each of these visits fall into the categorical CTP score 
of B, which has a range between 7-9. Table 9 shows the mean numerical CTP score for 
each visit and their relevant t-test p-values, when compared to baseline CTP scores. 
 
 
Table 9. Categorical CTP score distribution at each visit. N=number of patients (%). 




N (%) N (%) Change 
(%) 
N (%) Change 
(%) 
N (%) Change 
(%) 
 Baseline 1st follow-up 2nd follow-up Last follow-up 






-25.00 61 (51.26) 
30 (25.21) 
9 (7.56) 




B -11.11 -16.66 44.46 
C 133.33 200.00 333.33 
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Table 10. Numerical CTP score distribution at each visit. Obs=number of observations, 
SE=standard error of the mean, SD= standard deviation, LCI and UCI=lower and upper 
95% confidence intervals, T-test P-values are recorded for comparison of each visit CTP 




Obs Mean SE SD LCI UCI P-value 
Baseline 119 6.18 0.14 1.52 5.90 6.45  
1st follow-up 100 6.43 0.16 1.61 6.11 6.75 0.233 
2nd follow-up 99 6.67 0.17 1.68 6.33 7.00 0.0251 





4.2.2. Assessment of Tumor Response to Therapy Over Time
For assessing tumor response to therapy, RECIST and mRECIST were employed. 
Moreover, the longest axial diameter of the largest tumor (labeled as index tumor) was 
measured and diameter changes were recorded over time. Other descriptive tumor 
measures included tumor burden (single tumor, 2-3 tumors, or >3 tumors), presence of 
extrahepatic disease (absence, presence of distant metastases, presence of local lymph 
nodes) and presence of untargeted tumors after each TACE session.  
Figure 6. Spaghetti plot of fitted CTP scores by visit for each patient over the study 
period of three consecutive visits and the last before study exit visit. Visits are visually 
spaced equally, but not spaced equally in time. The red line represents the overall fitted 
regression line of CTP on visit number. 
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4.2.2.1 Assessment of tumor response according to RECIST 
At the first follow-up visit, 29 patients showed partial response, 79 had stable dis-
ease, while 11 progressed. At the second follow-up visit, 32 patients showed partial re-
sponse, 74 remained stable and 12 showed progressive disease. At the last follow-up, 28 
patients showed partial response, 59 had stable disease, while 32 progressed. Table 10 
shows the distribution of patient tumor response according to RECIST during each study 
time point, as well as the percent change from baseline in the number of responders per 
each RECIST category. Figure 7 shows a spaghetti plot of the fitted RECIST values over 
time (visit) for each patient. A Spearman's correlation coefficient was calculated to assess 
the relationship between RECIST and CTP score at each visit. There was no statistically 
significant correlation between RECIST and CTP at the first follow-up (rs = 0.01, p = 
0.88, Bonferroni adjusted), 2nd follow-up (rs = -0.07, p = 0.44, Bonferroni adjusted) or 
last follow-up (rs = -0.10, p = 0.25, Bonferroni adjusted).   
 
RECIST N % N % Change N % Change 
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Table 11. Patient tumor response to TACE according to RECIST, over time (study fol-
low-up visits). Percent change indicates the relative change in the number of patients for 





 1st follow-up 2nd follow-up Last follow-up 
SD 79 66.39 74 62.18 -6.33 59 49.58 -11.13 
PR 29 24.37 32 26.89 10.34 28 23.53 14.90 
PD 11 9.24 12 10.08 9.09 32 26.89 246.32 
Figure 7. Spaghetti plot of fitted RECIST response (fitted values) by visit for each 
patient over the study period of 3 consecutive visits and the last before study exit visit. 
The red line represents the overall fitted regression line of RECIST on visit number. 
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4.2.2.2. Tumor response according to mRECIST 
Complete tumor response according to mRECIST was achieved in 25 patients at 
the first follow-up visit. In addition, 25 patients showed partial response, 58 had stable 
disease and 11 patients showed progressive disease. At the end of the study period 9.24% 
of patients demonstrated complete response, while 41.18% demonstrated stable disease. 
Table 12 shows the distribution of tumor response according to mRECIST during each 
study time point, as well as the percent change from baseline in the number of responders 
per each mRECIST category as compared to the 1st visit. Figure 9 shows a spaghetti plot 
of the fitted RECIST values over time (visit) for each patient.  
A Spearman's correlation coefficient was calculated to assess the relationship 
between mRECIST and CTP score at each visit. There was no statistically significant 
correlation between mRECIST and CTP at the first follow-up (rs = 0.01, p = 0.86, 
Bonferroni adjusted), 2nd follow-up (rs = 0.05, p = 0.58, Bonferroni adjusted), or a last 




Table 12. Patient response to TACE according to mRECIST at each study visit.  N indi-
cates number of patients and % indicates percentage of patients for each mRECIST cate-
gory at each time point.  Percent change indicates the relative change in the number of 
patients at each visit compared to the first visit, by mRECIST category. 
 
 
mRECIST N % N % Change 
(%) 
N % Change 
(%) 
 1st follow-up 2nd follow-up Last follow-up 
SD 58 48.74 58 48.74 0 49 41.18 -15.52 
PR 25 21.01 33 27.73 32 27 22.69 8.00 
CR 25 21.01 17 14.29 -32 11 9.24 -56.00 





Figure 8. Spaghetti plot of fitted mRECIST response (fitted values) by visit for each 
patient over the study period of 3 consecutive visits and the last before study exit visit. The 
red line represents the overall fitted regression line of mRECIST on visit. 
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4.2.2.3. Tumor Response According To Tumor Size Change 
The mean longest baseline axial tumor diameter was 7.76 cm (SD=3.62, range 2-
16 cm). At 1st follow-up, the mean longest axial diameter was 7.09 cm (SD=3.92; range: 
0.8-19 cm, p=0.20, unpaired t-test, compared to baseline).). At the 2nd follow-up, the 
mean longest axial diameter further decreased to 6.95 cm (SD=3.95; range” 0.8-19 cm, 
p=0.12, unpaired t-test, compared to baseline).). At the final follow-up, mean axial tumor 
diameter was 6.74 (SD=3.87; range=0.8-19 cm, p=0.05, unpaired t-test, compared to 
baseline). Table 12 demonstrates the summary statistics for longest axial tumor size and 
percent change in longest axial tumor size over the study period. Compared to baseline, 
there is a statistically significant change in longest uni-dimensional tumor size at 6 
months (p=0.03, paired t-test). Compared to percent change in longest uni-dimensional 
tumor size between baseline and 1st visit, there is a statistically significant change 
between 2nd visit and baseline (p= 0.01, paired t-test), as well as between baseline and last 
visit (p=0.01, paired t-test). Figure 9 depicts a waterfall plot of the tumor size percent 
change for each individual and visit. Figure 10 depicts the longest uni-dimensional tumor 
size measurements over time (study visits). 
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Table 13. Descriptive statistics for longest axial tumor size and percent change in longest 
axial tumor size at each study visit. N indicates number of patients and parentheses 
indicate percentage of patients evaluated at each time point. N=number of observations, 
SD=standard deviation, min=minimum, max=maximum. P-values are recorded for 
unpaired t-test comparisons for tumor size and paired t-test comparisons for change (%) 





Visit N Mean SD Min Max P-value 
Baseline 94 7.76 3.62 2 16  
1st visit 117 7.09 3.92 0.8 19 0.20 
2nd visit 116 6.95 3.95 0.8 19 0.12 
Last visit 117 6.74 3.87 0.8 19 0.05 




1st visit 92 -19.95 98.85 -375 92  
2nd visit 92 -14.90 93.05 -275 92 0.01 





Figure 9. Waterfall plot of percent change in longest tumor uni-dimensional size for each 




Figure 10. Longest tumor uni-dimensional size measurements over study visits (p-
v
 




4.3.  Analysis Of Survival Estimates  
Mean overall survival was 18.85 months and median 14 months (range: 1-148 
months). During the study follow-up period, 95 of the 119 patients died. Figure 11. 





Figure 11. Kaplan-Meyer estimates of the overall probability of survival for the entir
cohort of patients with unresectable HCC that were treated with TACE. Survival 
estimates are calculated in months from the time of the first clinical visit to the 
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There was no statistically significant difference in survival estimates among age 
groups (p-value=0.30, log-rank test).  There was no statistically significant difference in 
survival estimates between male and female patients (p-value= 0.97, log-rank test). 
Similarly, there was no statistically significant difference in survival estimates among 
ethnicities (p=0.57, log-rank test.). There was no statistically significant difference in 
survival estimates among patients with different etiologies of hepatic cirrhosis (p=0.21, 
log-rank test). However, there were statistically significant differences in survival 
estimates among baseline ECOG performances with higher survival in ECOG 0 as 
compared to 1 and 2 (p=0.006, log-rank test, Figures 12 and 13). There were statistically 
significant differences in survival estimates by baseline CTP, with higher survival in CTP 
A as compared to CTP B and C (p-values=0.005, log-rank test, Figures 14 and 15). 
There was no statistically significant difference in survival estimates among patients with 
different 1st RECIST responses (p=0.30, log-rank test). There was no statistically 
significant difference in survival estimates among patients with different 1st mRECIST 
responses (p=0.38, log-rank test.). There was a statistically significant difference in 
survival estimates among baseline tumor size groups, with higher survival in patients 
with baseline tumor size < 5 cm (p-values=0.002, log-rank test, Figures 16 and 17). 
There was no statistically significant difference in survival estimates among patients with 
and without extrahepatic metastases (p=0.35, log-rank test). There was a statistically 
higher survival among patients without, as compared to with, baseline portal vein 
thrombosis  (p-values=0.005, log-rank test, Figure 18). Table 13 shows the time at risk, 
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number of observations, median and interquartile range of survival estimates among 





Figure 12. Kaplan Meier survival estimates according to baseline ECOG performance 





Figure 13. Kaplan Meier survival estimates according to baseline ECOG performance 














Figure 15. Kaplan Meier survival estimates according to baseline CTP scores (A vs. all 






Figure 16. Kaplan Meier survival estimates according to baseline longest uni-






Figure 17. Kaplan Meier survival estimates according to baseline longest uni-






Figure 18. Kaplan Meier survival estimates according to baseline portal vein thrombosis. 
(Log rank p-value=0.0037) 
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Table 14. Time at risk, number of observations, median and interquartile range of 
survival estimates among patients by baseline variables. P-values indicate significance by 
the log-rank test. 





N 25% 50% 75% p-
value 
Gender Male 1774 0.036 99 8 19 38 0.979 
 Female 469 0.031 20 14 23 26  
         
Age (years) 16-37 132 0.007 6 14   0.368 
 38-59 902 0.036 47 9 18 29  
 60-80 1081 0.037 59 10 21 36  
 81-102 127 0.031 6 8 11   
         
Ethnicity Caucasian 1409 0.038 79 10 21 31 0.241 
 African 
American 
356 0.039 22 8 19 47  
 Asian 1169 0.035 9 14 18 50  
 Other 307 0.016 8 15 36 148  
         
ECOG status 0 1666 0.028 86 12 23 50 0.006 
 1 531 0.058 44 5 11 24  
 2 46 0.021 3 11 11 .  
         
Cirrhosis Unknown/ 
cryptogenic 
725 0.040 34 8 14 38 0.215 
 Hepatitis B 415 0.026 23 11 27 50  
 Hepatitis C 510 0.043 35 11 21 26  
 Hepatitis B 
and alcohol 
85 0.058 5 3 6 36  
 Other* 508 0.025 22 14 24 47  
         
Baseline CPT 
score 
A 1668 0.028 80 11 23 50 0.015 
 B 529 0.058 36 6 12 24  
 C 46 0.021 3 11 11 .  
         
1st RECIST PR 660 0.028 29 10 21 50 0.300 
 SD 1365 0.041 79 9 17 29  
 
	   	  61 
 PD 218 0.022 11 11 48 48  
         
1st mRECIST CR 473 0.040 25 10 15 38 0.380 
 PR 590 0.027 25 11 23 52  
 SD 962 0.041 58 9 17 27  
 PD 218 0.023 11 11 48 48  
         
Baseline PVT No 1883 0.031 89 12 23 38 0.003 
 Yes 360 0.061 30 5 10 21  




2-4.99 561 0.016 24 23 47 52 0.002 
 5-7.99 361 0.038 24 14 20 27  
 8-11.99 640 0.035 32 9 17 36  
 12-16 179 0.072 14 5 7 21  
Extrahepatic 
metastases 
       0.351 




404 0.024 14 12 21 36  
 Distant 324 0.027 14 13 29 50  
 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none
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4.4. Cox Regression Analysis 
4.4.1. Univariate Cox Regression Analysis using Baseline (Time-Independent 
Variables) 
Time-independent Cox regression analysis included a univariate Cox regression 
analysis to evaluate the association between each baseline covariate and the hazard for 
death.  
Univariate Cox regression analysis showed that the hazard of death was higher in 
older patients compared to younger ones (for age group 37-59 years compared to less 
than 37 years, HR=5.49, 95% CI: 0.75-40.22, p=0.09; for age group 60-80 years 
compared to less than 37 years, HR= 5.30, 95% CI: 0.73-38.61, p=0.1; for age group 
older than 80 years compared to less than 37 years, HR=4.83, 95% CI: 0.54, 43.36, 
p=0.16).  The hazard of death was significantly higher for patients with ECOG status of 1 
or 2, as compared to 0 (HR =1.96, 95% CI: 1.23-3.11, p=0.004); CTP categorical score B 
as compared to A (HR= 2.07, 95% CI: 1.30, 3.28, p= 0.002); larger tumors compared to 
those < 5 cm (5-7.99 cm, HR=2.70, 95% CI=1.14, 6.37, p=0.024; 8-11.99 cm, HR= 2.60, 
95% CI= 1.19, 5.99, p< 0.016; larger than 12 cm, HR= 4/85, 95% CI: 2.05-11.49, 
p<0.0001); and presence of portal vein thrombosis at baseline (HR=2.074, 95% CI: 1.25, 
3.43, p=0.004). Univariate Cox regression analysis showed that the hazard of death was 
slightly lower in patients with HBV (HR=0.59, 95% CI: 0.28-1.16, p=0.16) and in 
patients with cirrhosis of other etiology, including hereditary hemochromatosis 
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(HR=0.56, 95% CI: 0.27-1.13, p=0.11). Table 14 provides the estimated hazard ratio 
(HR) for death for each baseline covariate, the corresponding 95% confidence interval 
(lower and upper CI) and p-value for the corresponding Wald test of the univariate Cox 
regression analyses.  All of the statistically significant variables, defined as those with a 
Wald test p-value of less than 0.20 (Greenland, 1989) from the univariate analysis were 
subsequently included in the multivariable model in order to assess the combined effect 
of all risk factors of early mortality and to eliminate the effect of confounding factors. 
Note that in addition to the cutoff value of p<0.20, clinical criteria were also employed 
for multivariable modeling. 
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Table 15. Univariate Cox regression analysis of baseline covariates and hazard ratio for 
death during the study period of patients with unresectable HCC treated with TACE. 
Values are unadjusted. HR=Hazard Ratio, LCI=lower 95% CI, UCI=Upper 95% CI, P-
value=Wald test P-value. 
 
 HR z P-value LCI UCI 
Age (years)      
16-37.5 1     
38-59 5.49 1.67 0.09 0.75 40.22 
60-80 5.30 1.65 0.10 0.73 38.61 
>80 4.83 1.41 0.16 0.54 43.36 
Gender      
Male 1     
Female 1.01 0.03 0.98 0.57 1.80 
Ethnicity      
Caucasian 1     
African American 1.07 0.23 0.82 0.59 1.93 
Asian 0.94 -0.14 0.89 0.40 2.19 
Other 0.47 -1.43 0.15 0.17 1.32 
Hepatic Cirrhosis      
HCV 1     
Unknown/cryptogenic 0.95 -0.16 0.88 0.54 1.70 
HBV 0.59 -1.42 0.16 0.28 1.22 
HBV and Alcohol 1.32 0.56 0.58 0.49 3.57 
Other* 0.56 -1.61 0.11 0.27 1.13 
Baseline ECOG score      
0 1     
1 or 2 1.96 2.88 0.004 1.23 3.10 
Extrahepatic Metastases      
None 1     
Regional Lymph nodes 0.70 -0.97 0.33 0.35 1.43 
Distant Metastasis 0.66 -1.17 0.24 0.33 1.33 
Baseline Portal Vein 
Thrombosis 
     
No 1     
Yes 2.074 2.840 0.004 1.254 3.430 
Baseline Tumor Burden      
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Single Tumor 1     
2-3 tumors 0.91 -0.24 0.81 0.44 1.91 
>3 tumors 0.91 -0.42 0.68 0.57 1.45 
Baseline Tumor Size 
(cm) 
     
2-4.99  1     
5-7.99  2.70 2.27 0.023 1.14 6.37 
8-11.99  2.60 2.40 0.016 1.19 5.69 
12-16  4.85 3.59 <0.0001 2.05 11.49 
Baseline CTP score      
A 1     
B 2.07 3.07 0.002 1.30 3.28 
C 0.75 -0.29 0.77 0.10 5.45 
1st mRECIST      
CR 1     
PR 0.71 -0.99 0.32 0.36 1.40 
SD 1.07 0.25 0.80 0.62 1.86 
PD 0.58 -1.07 0.29 0.22 1.57 
1st RECIST      
PR 1     
SD 1.35 1.11 0.27 0.79 2.30 
PD 0.76 -0.54 0.59 0.28 2.06 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none 
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4.4.2. Assessment of PH assumption for baseline covariates  
To visually inspect the proportional hazards assumption, "Stphplot" plots –ln (-ln 
(survival)) or “complementary log-log” survival curves for each variable versus ln (time) 
were constructed. The proportional hazards assumption is not violated when the curves 
are parallel. Figure 19 shows the complementary log-log survival plot of baseline portal 
vein thrombosis versus ln (time), where the PH assumption seems not to be violated. 
Figure 20 shows the complementary log-log survival plot of baseline ECOG 
performance status versus ln (time), where again,  the PH assumption seems not to be 
violated. Figure 21 shows the complementary log-log survival plot of baseline tumor size 
versus ln(time). The two lines (for baseline tumor size >5 cm and =<4.99 cm) do not run 
parallel over time. 
Following, we generated plots of the generalized linear regression of the scaled 
Schoenfeld residuals of selected covariates on time and employed the Schoenfeld test 
(stphtest), to investigate the linear trend between the Schoenfeld residuals and “log” 
survival time. Figure 22 shows the generalized linear regression of the scaled Schoenfeld 
residuals of tumor size on time (p=0.21 for the global test). Table 15 provides the 
Schoenfeld test p-values (prob>chi2), correlation coefficient (r), the chi2 test values and 
degrees of freedom (df) for all tested covariates. The global test output from the 
Schoenfeld test is not statistically significant, indicating an absence of evidence to 
contradict the proportionality assumption. The test output for African American ethnicity 
is statistically significant (p=0.04), indicating that proportionality is violated in this 
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predictor. Stratification according to ethnicity may be suggested as an alternative to 




Figure 19. Complementary log-log survival plot of baseline portal vein thrombosis 









Figure 20. Complementary log-log plot of baseline ECOG status versus ln (time). The 







Figure 21. Complementary log-log plot of baseline tumor size versus ln (time). The PH 







Figure 22. Graph of generalized linear regression of the scaled Schoenfeld residuals of 
baseline tumor size on time. The red line is a horizontal reference line at y=0.  The 
curved blue line is a LOWESS fit (locally weighted scatterplot smoothing) curve of the 
residuals on time, to facilitate pattern detection.  
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Table 16. Schoenfeld tests of proportional hazards assumption for covariates included in 
the multivariable Cox regression analysis. Time is expressed as log survival time. 
Prob>chi2=Schoenfeld test p-value, rho= correlation coefficient, df=the chi2 test values 
and degrees of freedom for all tested covariates.  
 
Time:  Log (t) rho chi2 df Prob>chi2 
Age (years)     
16-37.5 (base) . . 1 . 
38-59 -0.036 0.07 1 0.787 
60-80 -0.033 0.06 1 0.801 
>80 -0.212 2.61 1 0.106 
Ethnicity     
Caucasian (base) . . 1 . 
African American -0.233 4.28 1 0.04 
Asian 0.006 0 1 0.950 
Other -0.10 1.08 1 0.300 
Baseline Portal Vein 
Thrombosis 
    
No (base) . . 1 . 
Yes -0.122 1.16 1 0.281 
Baseline CTP score     
A (base) . . 1 . 
B -0.117 0.77 1 0.380 
C 0.032 0.08 1 0.773 
Hepatic Cirrhosis     
HCV (base) . . 1 . 
Unknown/cryptogenic -0.1702 2.24 1 0.13 
HBV -0.119 1.06 1 0.30 
HBV and Alcohol -0.059 0.27 1 0.60 
Other* 0.015 0.01 1 0.90 
Baseline ECOG score     
0 (base) . . 1 . 
1 0.008 0 1 0.44 
Baseline Tumor Size 
(cm) 
    
2-4.99 (base) . . 1 . 
5-7.99  0.160 1.76 1 0.18 
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8-11.99  0.160 1.61 1 0.20 
12-16 -0.012 0.01 1 0.91 
     
Global test  21.37        17 0.21 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none 
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4.4.2. Time-independent Multivariable Cox Regression Analysis 
Time-independent multivariable Cox regression analysis was performed to evaluate 
how baseline covariates jointly affect patient survival. Statistically significant covariates 
(p<0.2) from the univariate Cox regression models were incorporated into the 
multivariable Cox regression analysis. Table 16 shows the results of the multivariable 
Cox regression analysis of baseline covariates on the effect of relative hazard of death for 
the study cohort (Model A).  
Given that the goal of the multivariable Cox model is to assess the effect of TACE 
on overall survival, while controlling for putative confounding variables, potential 
confounders were examined by using the change-in-estimate method and by comparing 
unadjusted and adjusted coefficients of HR. In this method, a potential confounder was 
included in the model if it changed the coefficient of the primary exposure variable (HR) 
by 10 percent.  This approach is consistent with the definition of confounding, with 
confounding being present if the unadjusted effect differs from the effect adjusted for 
putative confounders (Rothman, Greenland, & Lash, 2008). Table 17 shows the 
comparison of unadjusted and adjusted hazard ratios of death for baseline variables tested 
in univariate and multivariable (Model A) Cox regression analyses. The variables of age, 
ethnicity, ECOG status, etiology of cirrhosis and CTP score had more than 10% in 
change between unadjusted and adjusted effect estimates, indicating that these are 
confounders of the relationship between the predictors of portal vein thrombosis and 
tumor size on overall survival. 
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Table 18 shows the results of the multivariable Cox regression analysis of baseline 
covariates on the effect of relative hazard of death, stratified by ethnicity (Model B). 
Stratification by ethnicity was performed after testing for PH assumption using the 
Schoenfeld (stph) test, where it was observed that PH proportionality for African 
American ethnicity was violated (global test, p-value=0.04). The multivariable Cox 
regression analysis shows that the presence of portal venous thrombosis (HR=2.77, 95% 
CI=1.43-5.47, p=0.002) and baseline tumor size less than 5 cm (5-7.99 cm: HR=3.62, 
95% CI=1.43-9.15, p=0.007; 8-11.99 cm: HR=3.24, 95% CI=1.30-8.08, p=0.011; >12 
cm: HR=9.51, 95% CI=2.88-31.41, p<0.0001) are independent statistically significant 
predictors of overall survival. After regrouping patients according to the cut-off value of 
5 cm in uni-dimensional tumor size, patients with smaller tumors had a statistically 
significant higher hazard of death (HR=3.60, 95% CI=1.60-8.09, p=0.002). Stratified by 
ethnicity, the hazard ratio of mortality for patients with unresectable HCC and portal 
venous thrombosis before 1st TACE is 2.68 times higher (95% CI=1.38-5.22) compared 
to patients without portal venous thrombosis adjusted for age, etiology of cirrhosis, 
ECOG performance status, tumor size and CTP score. 
A parsimonious model (Model C) was subsequently constructed with stepwise 
backward selection, removing one variable at a time from the full Model B in order of 
least significance, until all retained variables had p<0.05 (p for removal 0.05). ). Table 19 
shows the results of the multivariable Cox regression analysis of Model C, with baseline 
covariates of portal vein thrombosis, etiology of hepatic cirrhosis and tumor size on the 
effect of relative hazard of death, stratified by ethnicity. As in Model B, we observed a 
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higher hazard ratio of death for patients with portal vein thrombosis (HR= 2.47, 95% CI= 
1.32-4.64, p=0.01) and larger than 5 cm tumors (5-7.99 cm, HR= 3.16, 95% CI=1.27-
7.90, p=0.01; 8-11.99 cm, HR=3.37, 95% CI=1.37-8.30, p=0.01; >12 cm, HR=3.56, 95% 
CI= 2.46-22.53, p<0.0001). 
The best fit of the three models was determined by the Akaike Information 
Criterion (AIC, (Akaike, 1974) and the Bayesian Information Criterion (BIC, (Schwarz, 
1978). Models B and C have comparably low AIC and BIC values, with Model C having 
the lowest AIC and BIC values and being more parsimonious (Table 20). 
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Table 17. Multivariable Cox regression analysis of the hazard ratio for death, adjusted 
for baseline covariates of baseline age, ethnicity, etiology of cirrhosis, ECOG status, 
presence of portal venous thrombosis, tumor size and CTP score (Model A). HR=Hazard 
Ratio, LCI=lower 95% CI, UCI=Upper 95% CI, P-value=Wald test P-value. 
 
 MODEL A HR z P-value LCI UCI 
Age (years)      
16-37.5 1     
38-59 0.89 -0.10 0.92 0.10 7.63 
60-80 1.22 0.18 0.86 0.15 9.87 
>80 1.35 0.23 0.82 0.10 17.66 
Ethnicity      
Caucasian 1.00     
African American 1.00 0.00 0.998 0.46 2.16 
Asian 0.34 -1.67 0.10 0.09 1.21 
Other 0.27 -1.79 0.07 0.06 1.14 
Hepatic Cirrhosis      
HCV 1.00     
HBV 0.58 -1.24 0.22 0.25 1.37 
Unknown/cryptogenic 0.42 -1.68 0.09 0.16 1.15 
HBV and Alcohol 2.92 1.65 0.10 0.82 10.49 
Other* 1.02 0.04 0.97 0.41 2.52 
Baseline ECOG 
status 
     
0 1.00     
1 or 2 1.25 0.35 0.723 0.36 4.37 
Baseline Portal Vein 
Thrombosis 
     
No 1.00     
Yes 2.77 3.03 0.002 1.43 5.37 
Baseline Tumor Size 
(cm) 
     
2-4.99  1.00     
5-7.99  3.62 2.72 0.007 1.43 9.15 
8-11.99  3.24 2.53 0.011 1.30 8.08 
12-16 9.51 3.69 0.000 2.88 31.41 
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Baseline CTP score      
A 1.00     
B 1.31 0.45 0.65 0.40 4.29 
C 0.49 -0.65 0.52 0.06 4.19 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none. 
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Table 18. Comparison of unadjusted and adjusted hazard ratios of variables for 
confounding estimation according to the change-in-estimate method. HR=Hazard Ratio, 
LCI=lower 95% CI, UCI=Upper 95% CI, P-value=Wald test P-value, Change %: percent 
change of unadjusted minus adjusted HR for each variable that entered the multivariable 
time-independent Model A. 
 HR  P-value LCI UCI HR P-value LCI UCI Change, 
% 
                         Univariate  Multivariable  
Age 
(years) 
         
16-37.5 1.00    1.00     
38-59 5.49 0.09 0.75 40.22 0.89 0.92 0.10 7.63 83.79 
60-80 5.30 0.10 0.73 38.61 1.22 0.86 0.15 9.87 76.98 
>80 4.83 0.16 0.54 43.36 1.35 0.82 0.10 17.66 72.05 
Gender          
Male 1.00         
Female 1.01 0.98 0.57 1.80      
Ethnicity          
Caucasian 1.00    1.00     
African 
American 
1.07 0.82 0.59 1.93 1.00 0.998 0.46 2.16 6.54 
Asian 0.94 0.89 0.40 2.19 0.34 0.10 0.09 1.21 63.83 
Other* 0.47 0.15 0.17 1.32 0.27 0.07 0.06 1.14 42.55 
Hepatic 
Cirrhosis 
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HCV 1.00    1.00     
Unknown/ 
cryptogenic 
0.95 0.88 0.54 1.70 0.58 0.22 0.25 1.37  
HBV 0.59 0.16 0.28 1.22 0.42 0.09 0.16 1.15  
HBV and 
Alcohol 
1.32 0.58 0.49 3.57 2.92 0.10 0.82 10.49  




         
0 1.00    1.00     




         




0.70 0.33 0.35 1.43      
Distant 
Metastasis 
0.66 0.24 0.33 1.33      
Baseline 
PVT 
         
No 1.00    1.00     
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Single 
Tumor 
1.00         
2-3 tumors 0.91 0.81 0.44 1.91      




         
2-4.99  1.00    1.00     
5-7.99 2.70 0.023 1.14 6.37 3.62 0.007 1.43 9.15 -34.07 
8-11.99 2.60 0.016 1.19 5.69 3.24 0.011 1.30 8.08 -24.62 
12-16  4.85 0.000 2.05 11.49 9.51 0.000 2.88 31.41 -96.08 
Baseline 
CTP score 
         
A 1.00    1.00     
B 2.07 0.002 1.30 3.28 1.31 0.65 0.40 4.29 36.71 
C 0.75 0.77 0.10 5.45 0.49 0.52 0.06 4.19 34.67 
1st 
mRECIST 
         
CR 1.00         
PR 0.71 0.32 0.36 1.40      
SD 1.07 0.80 0.62 1.86      
PD 0.58 0.29 0.22 1.57      
1st 
RECIST 
         
PR 1.00         
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SD 1.35 0.27 0.79 2.30      
PD 0.76 0.59 0.28 2.06      
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none. 
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Table 19. Multivariable Cox regression analysis of the hazard ratio for death adjusted for 
baseline covariates and stratified by ethnicity (Model B), so as to minimize PH non-
proportionality of this variable (Schoenfeld global test for African-American ethnicity, 
p=0.04).  Baseline portal venous thrombosis and baseline tumor size remain as 
statistically significant covariates of overall survival, with slight HR reductions of the 
risk of death. HR=Hazard Ratio, LCI=lower 95% CI, UCI=Upper 95% CI, P-value=Wald 
test P-value. 
 MODEL B HR z P-value LCI UCI 
Age (years)      
16-37.5 1     
38-59 1.135 0.120 0.908 0.133 9.679 
60-80 1.418 0.320 0.745 0.172 11.689 
>80 1.835 0.470 0.641 0.143 23.565 
Baseline Portal Vein 
Thrombosis 
     
No 1.000     
Yes 2.683 2.910 0.004 1.379 5.218 
Baseline CTP score      
A 1.000     
B 1.360 0.510 0.608 0.421 4.394 
C 0.556 -0.530 0.595 0.064 4.851 
Hepatic Cirrhosis      
HCV 1.000     
HBV 0.546 -1.170 0.241 0.198 1.503 
Unknown/cryptogenic 0.672 -0.890 0.375 0.279 1.617 
HBV and Alcohol 2.640 1.410 0.158 0.686 10.154 
Other* 1.298 0.560 0.575 0.521 3.237 
Baseline ECOG score      
0 1.000     
1o r 2  1.039 0.060 0.952 0.303 3.562 
Baseline Tumor Size 
(cm) 
     
<4.99  1.000     
5-7.99  3.097 2.360 0.018 1.210 7.930 
8-11.99  3.178 2.420 0.015 1.247 8.100 
12-16  7.396 3.210 0.001 2.181 25.079 
  Stratified by Ethnicity 
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*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none.   
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Table 20. Multivariable Cox regression analysis of the hazard ratio for death adjusted for 
baseline covariates of portal vein thrombosis, etiology of hepatic cirrhosis and tumor size 
(Model C), stratified by ethnicity (as in Model B, Table 19.). Stratification by ethnicity 
was performed so as to minimize non-proportionality for the African-American ethnicity 
variable (Schoenfeld test p-value=0.04).  HR=Hazard Ratio, LCI=lower 95% CI, 
UCI=Upper 95% CI, P-value=Wald test P-value. 
 
 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-










MODEL C HR z P-value LCI. UCI 
Portal Vein 
Thrombosis 
     
No 1 (base)    
Yes 2.47 2.82 0.01 1.32 4.64 
Hepatic Cirrhosis      
HCV 1.00 (base)    
HBV 0.49 -1.48 0.14 0.19 1.26 
Unknown/cryptogenic 0.67 -1.01 0.31 0.31 1.45 
HBV and Alcohol 2.42 1.34 0.18 0.67 8.82 
Other 1.38 0.73 0.46 0.59 3.24 
Tumor Size (cm)      
2-4.99   1.00 (base)     
5-7.99  3.16 2.47 0.01 1.27 7.90 
8-11.99  3.37 2.64 0.01 1.37 8.30 
12-16  7.45 3.56 0.00 2.46 22.53 
  Stratified by Ethnicity 
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Table 21. Comparison of model fitting and adequacy for multivariable time-independent 
Cox Models A-C, according to Akaike information criterion (AIC) and Bayesian 
Information Criterion (BIC).  Models with lowest AIC and BIC are preferable. Models B 
and C have similar AIC and BIC values. Obs=number of observations, ll(null)=log-
likelihood of the null model, ll(model)=log-likelihood of the fitted model , df=degrees of 
freedom, AIC=Akaike Information Criterion, BIC= Bayesian Information Criterion. 
 
Model Obs ll(null) ll(model) df AIC BIC 
A 93 -204.87 -184.94 17 403.88 446.94 
B 93 -152.26 -137.60 14 303.19 338.65 
C 94 -156.39 -142.64 8 301.28 321.63 
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4.4.4.  Time-dependent Univariate Cox Regression Analysis 
Time-dependent covariates in the univariate Cox model included covariates that 
were collected longitudinally over time, during each visit. These included the variables of 
portal vein thrombosis, presence of metastases, tumor response according to mRECIST 
and RECIST, uni-dimensional longest diameter tumor size, and CTP score. In addition, 
the baseline variables of age, ethnicity, hepatic cirrhosis and ECOG performance status 
were also considered to be collected longitudinally, but did not change over time. 
Time-dependent Cox regression analysis included a univariate Cox regression 
analysis to evaluate the association between each covariate (accounting for it varying 
over time) and the hazard for death. Univariate Cox regression analysis showed that the 
hazard of death was significantly higher for older patients, compared to patients younger 
than 37.5 years old (38-59 years old, HR=5.36, 95% CI=0.64-45.16, p=0.12; 60-80 years 
old, HR= 4.72, 95% CI=0.57-38.56, p=0.15), patients with ECOG score of 1 or 2, 
compared to 0 (HR=1.88, 95% CI=1.19-2.95, p=0.01) and patients with CTP score C, 
compared to patients with CTP score A (HR=2.06, 95% CI=0.89-4.80, p-0.09). Patients 
with ethnicity other than Caucasian, African American or Asian had lower risk of death 
compared to Caucasians (HR= 0.39, 95% CI=0.11-1.39, p=0.15).  Patients with distant 
metastases had lower risk of death compared to those without (HR=0.49, 95% CI=0.27-
0.89, p=0.02). Patients with enlarged regional lymph nodes had also lower risk of death 
compared to those without (HR=0.28, 95% CI=0.07-1.19, p=0.09).  Patients with HBV-
related cirrhosis had lower risk of death compared to patients with HCV-related cirrhosis 
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(HR= 0.57, 95% CI=0.27-1.19, p=0.13). Patients with progressive disease according to 
mRECIST had also lower risk of death compared to those with partial response 
(HR=0.53, 95% CI=0.25-1.12, p=0.1). Table 21 shows the results of the univariate Cox 
regression analysis for each time-dependent covariate. 
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Table 22. Univariate Cox regression analysis of time-dependent covariates and hazard 
ratio for death during the study period of patients with unresectable HCC treated with 
TACE. Values are unadjusted. HR=Hazard Ratio LCI=lower 95% CI, UCI=Upper 95% 
CI, P-value=Wald test P-value.  
 HR z P-value LCI UCI 
Age (years)      
16-37.5 1 (base)    
38-59 5.36 1.54 0.12 0.64 45.16 
60-80 4.72 1.44 0.15 0.57 38.96 
>80 5.01 1.24 0.22 0.39 64.71 
Gender      
Male 1 (base)    
Female 1.15 0.49 0.62 0.67 1.97 
Ethnicity      
Caucasian 1 (base)    
African American 1.22 0.62 0.54 0.65 2.30 
Asian 1.10 0.25 0.80 0.54 2.25 
Other* 0.39 -1.46 0.15 0.11 1.39 
Hepatic Cirrhosis      
HCV 1.00 (base)    
HBV 0.57 -1.50 0.13 0.27 1.19 
Unknown/cryptogenic 0.93 -0.25 0.80 0.53 1.63 
HBV and Alcohol 1.06 0.12 0.90 0.39 2.89 
Other 0.48 -2.08 0.04 0.24 0.96 
ECOG score      
0 1 (base)    
1 or 2  1.98 3.07 0.002 1.28 3.07 
Portal Vein 
Thrombosis 
     
No  1 (base)    
Yes 1.22 0.85 0.39 0.77 1.93 
Extrahepatic 
Metastases 
     
None 1 (base)    
Regional lymph 
nodes 
0.69 -1.03 0.30 0.34 1.40 
Distant Metastasis 0.72 -1.43 0.15 0.47 1.12q 
mRECIST      
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CR 1 (base)    
PR 0.95 -0.14 0.89 0.46 1.95 
SD 0.74 -0.95 0.34 0.40 1.38 
PD 0.53 -1.67 0.10 0.25 1.12 
RECIST      
PR 1 (base)    
SD 0.84 0.56 0.47 1.50 0.56 
PD 0.56 0.13 0.26 1.18 0.13 
CTP score      
A 1 (base)    
B 1.09 0.35 0.73 0.67 1.78 
C 2.06 1.68 0.09 0.89 4.80 
Tumor Size (cm)      
2-4.99  1 (base)    
5-7.99  0.77 -0.86 0.39 0.42 1.40 
8-11.99  1.02 0.06 0.95 0.55 1.88 
12-16 0.94 -0.17 0.87 0.44 1.99 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none. 
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4.4.5.  Time-dependent Multivariable Cox Regression Analysis 
Time-dependent multivariable Cox regression analysis was performed to evaluate 
how time-varying covariates jointly affect patient survival. For direct comparison of the 
multivariable time-independent estimates, two multivariable time-dependent models were 
examined; Model A and Model B. For Time-dependent Model A, statistically significant 
covariates (p<0.20) from the univariate time-dependent Cox regression analyses entered 
the multivariable time-dependent Cox regression analysis. These included the covariates 
of ethnicity, type of cirrhosis, ECOG status, extrahepatic metastases, mRECIST and CTP 
scores.  Stratification by age was performed, to reduce PH non-proportionality 
(Schoenfeld global test for age, p=0.0046). For Time-dependent Model B, all covariates 
from the multivariable time-independent Cox regression analysis of baseline covariates 
(time-independent Model A) were entered.  
Table 22 shows the results of the time-dependent multivariable Cox regression 
analysis of time-varying covariates (Time-dependent Model A) that achieved statistical 
significance (p<0.2)  in the univariate analysis, on the relative hazard of death. Table 23. 
shows the results of the time-dependent multivariable Cox regression analysis of time-
varying covariates (Time-dependent Model B) that entered the multivariable Cox 
regression analysis of baseline covariates (Model A of Table 18.). Table 24 shows the 
comparison between the time-independent and time-dependent multivariable Cox 
regression analyses. While baseline portal venous thrombosis and baseline tumor size 
were identified as statistically significant predictors of overall survival among time-
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independent covariates, ECOG performance status and CTP score were identified as 
statistically significant predictors of overall survival among time-dependent predictors.
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Table 23. Multivariable Cox regression analysis of the hazard ratio for death, adjusted 
for time-dependent covariates (Model A) of hepatic cirrhosis, ECOG status, portal 
venous thrombosis, extrahepatic metastases, tumor response according to mRECIST and 
CTP score. Baseline ECOG status and CTP score are statistically significant predictors of 
overall survival (p=0.02, respectively). HR=Hazard Ratio LCI=lower 95% CI, 
UCI=Upper 95% CI, P-value=Wald test P-value. 
Time-dependent MODEL A      
 HR z P-value LCI UCI 
Hepatic Cirrhosis      
HCV 0.90 -0.32 0.75 0.46 1.74 
HBV 0.95 -0.15 0.88 0.48 1.86 
Unknown/cryptogenic 1.51 0.85 0.40 0.58 3.89 
HBV and Alcohol 0.54 -1.57 0.12 0.25 1.16 
Other* 0.90 -0.32 0.75 0.46 1.74 
ECOG score      
0 1.00 (base)    
1 or 2 1.83 2.36 0.02 1.11 3.03 
Extrahepatic Metastases      
Absent 1.00 (base)    
Regional lymph nodes 0.93 -0.20 0.84 0.49 1.80 
Distant Metastasis 0.69 -1.48 0.14 0.43 1.13 
Portal Vein Thrombosis      
No  1.00 (base)    
Yes 1.26 1.43 0.15 0.92 1.74 
mRECIST      
CR 1.00 (base)    
PR 1.16 0.69 0.49 0.77 1.74 
SD 1.38 1.62 0.11 0.93 2.05 
PD 0.76 -0.81 0.42 0.40 1.46 
CTP score      
A 1.00 (base)    
B 1.46 2.33 0.02 1.06 2.01 
C 1.24 0.56 0.57 0.59 2.58 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none. 
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Table 24. Multivariable Cox regression analysis of the hazard ratio for death, adjusted 
for time-dependent covariates (Time-dependent Model B) of age, ethnicity, hepatic 
cirrhosis, ECOG status, portal venous thrombosis, extrahepatic metastases, tumor size 
and CTP score. ECOG score of 1 (p=0.05) and CTP score of B (p=0.02) are independent 
predictors of overall survival. HR=Hazard Ratio, LCI=lower 95% CI, UCI=Upper 95% 
CI, P-value=Wald test P-value. 
 
Time-dependent MODEL B HR z P-value LCI UCI 
Age (years)   
16-37.5 1.00 (base)    
38-59 3.84 1.19 0.23 0.42 35.14 
60-80 4.22 1.29 0.20 0.47 37.50 
>80 5.71 1.39 0.16 0.49 65.99 
Ethnicity      
Caucasian 1.00     
African American 1.03 0.08 0.94 0.50 2.12 
Asian 1.10 0.22 0.83 0.47 2.57 
Other 0.52 -1.17 0.24 0.18 1.55 
Hepatic Cirrhosis      
HCV 1.00     
HBV 0.76 -0.75 0.45 0.37 1.56 
Unknown/cryptogenic 0.80 -0.63 0.53 0.40 1.60 
HBV and Alcohol 1.67 0.94 0.35 0.57 4.87 
Other 0.56 -1.48 0.14 0.26 1.21 
ECOG status      
0 1.00     
1 or 2 1.80 1.96 0.05 1.00 3.25 
Portal Vein Thrombosis      
No 1.00     
Yes 1.04 0.19 0.85 0.71 1.51 
Tumor Size      
2-4.99 cm 1.00     
5-7.99 cm 0.98 -0.06 0.95 0.62 1.58 
8-11.99 cm 0.95 -0.23 0.82 0.60 1.49 
12-16 cm 1.25 0.80 0.43 0.72 2.16 
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CTP score      
A 1.00     
B 1.50 2.32 0.02 1.07 2.12 
C 1.67 1.48 0.14 0.85 3.27 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none. 
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Table 25. Comparison of results between time-independent and time-dependent 
multivariable Cox regression analyses of the hazard ratio for death. Variables that were 
included in the multivariable Cox regression analysis of baseline covariates were 
considered for this comparison. HR=Hazard Ratio, LCI=lower 95% CI, UCI=Upper 95% 
CI, P-value=Wald test P-value. 
  HR z  P-
value 





Time independent   Time-dependent 
16-37.5 1.00         1.00     
38-59 0.89 -0.1 0.92 0.1 7.63 3.84 1.19 0.23 0.42 35.14 
60-80 1.22 0.18 0.86 0.15 9.87 4.22 1.29 0.20 0.47 37.50 
>80 1.35 0.23 0.82 0.1 17.66 5.71 1.39 0.16 0.49 65.99 
Ethnicity    
Caucasia
n 
1.00         1.00     
African 
American 
1.00 0 0.99 0.46 2.16 1.03 0.08 0.94 0.50 2.12 
Asian 0.34 -1.67 0.1 0.09 1.21 1.10 0.22 0.83 0.47 2.57 





HCV 1.00         1.00     




0.42 -1.68 0.09 0.16 1.15 0.80 -0.63 0.53 0.40 1.60 
HBV and 
Alcohol 
2.92 1.65 0.1 0.82 10.49 1.67 0.94 0.35 0.57 4.87 
Other 1.02 0.04 0.97 0.41 2.52 0.56 -1.48 0.14 0.26 1.21 
ECOG 
status 
   
0 1.00         1.00     
1 1.25 0.35 0.72 0.36 4.37 1.80 1.96 0.05 1.00 3.25 
PVT                
No 1.00         1.00     
Yes 2.77 3.03 0.002 1.43 5.37 1.04 0.19 0.85 0.71 1.51 
 




2-4.99  1.00         1.00     
5-7.99 3.62 2.72 0.007 1.43 9.15 0.98 -0.06 0.95 0.62 1.58 
8-11.99 3.24 2.53 0.01 1.3 8.08 0.95 -0.23 0.82 0.60 1.49 
12-16  9.51 3.69 0.00 2.88 31.41 1.25 0.80 0.43 0.72 2.16 
CTP 
score 
   
A 1.00         1.00     
B 1.31 0.45 0.65 0.4 4.29 1.50 2.32 0.02 1.07 2.12 
C 0.49 -0.65 0.52 0.06 4.19 1.67 1.48 0.14 0.85 3.27 
*Includes combination of alcoholic and HCV cirrhosis, combination of alcoholic and HBV/HCV 
cirrhosis, hemochromatosis, hemochromatosis and HBV, hemochromatosis and HCV, non-
alcoholic steatohepatitis, or none. 
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CHAPTER 5. DISCUSSION AND CONCLUSIONS 
5.1. Clinical implications 
The purpose of this work was to determine whether baseline and longitudinally 
collected clinical and imaging data, tumor response to therapy and liver function are 
predictive of overall survival in patients with unresectable HCC treated with TACE. We 
first assessed whether time-independent (baseline) covariates are predictive of overall 
survival and identified that baseline portal vein thrombosis and baseline uni-dimensional 
tumor size are predictive of overall survival. We subsequently assessed whether time-
dependent (longitudinal) covariates are predictive of overall survival and identified that 
ECOG performance status and CTP score as statistically significant predictors of overall 
survival. Since the time-dependent multivariable Cox regression models have almost 3 
times more observations (in the form of repeated measures) than the time-independent 
multivariable Cox regression models, the former may provide with more robust 
information associated with the temporal changes in information of selected variables. 
The time-dependent multivariable Cox regression models illustrated in this work may 
provide a useful example and guidance for clinicians wishing to further explore the value 
of longitudinally collected covariates and their effect on overall survival. 
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5.1.1. Predictors of overall survival according to time-dependent Cox PH models  
5.1.1.1. ECOG performance status 
 
Our findings from the time-dependent analysis of the longitudinal study suggest a 
higher hazard of death for patients with ECOG status of 1, as compared to an ECOG 
status of 0 (time-dependent multivariable Model A, HR=1.83, 95% CI=1.11-3.03, 
p=0.02; time-dependent multivariable Model B, HR=1.80, 95% CI=1.00-3.25, p=0.05). 
This is in accordance with two very recently published research studies as well as the 
2015 Japanese clinical guidelines, suggesting that TACE should be reserved for patients 
with ECOG performance status of 0 (Hsu et al., 2013; Nishikawa et al., 2015; R. T. Poon 
et al., 2015). None of the other clinical studies, however, utilized time-dependent Cox PH 
models for assessing the effect of ECOG status over time on overall survival. 
5.1.1.2.  Child-Turcotte Pugh score 
Our findings from the time-dependent analysis of the longitudinal study suggest a 
higher hazard of death for patients with CTP score of B, as compared to CTP score of A 
(time-dependent multivariable Model B, HR=1.50, 95% CI=1.07-2.12, p=0.02). Patients 
with CTP score of C had an even higher hazard of death (HR=1.67, 95% CI=0.85-3.27, 
p=0.14), but results did not reach statistically significance due to the small sample size of 
patients with CTP score of C.  On the numerical CTP score scale, we observed 
statistically significant changes in the CTP score over time, particularly at 6 months and 
at study exit. This is in accordance with previously published research on the prognosis 
of the co-existence of two disease entities in patients with HCC, namely cancer and 
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cirrhosis, on overall survival(Barman et al., 2014; Brown et al., 2004). Similarly, none of 
the clinical studies, however, utilized time-dependent Cox PH models for assessing the 
effect of CTP score over time on overall survival. 
 
5.1.2.  Predictors of overall survival according to time-independent baseline covariate 
data analysis 
5.1.2.1. Portal vein thrombosis  
Our findings from the multivariable Cox regression analysis of time-independent 
(baseline) covariates suggest that baseline portal vein thrombosis is an independent 
predictor of overall survival in patients with unresectable HCC treated with TACE ((HR= 
2.47, 95% CI= 1.32-4.64, p=0.01), after adjusting for hepatic cirrhosis (time-independent 
parsimonious Model C). Patients with portal vein thrombosis had a median survival of 10 
months, compared to a median survival of 23 months in patients without portal vein 
thrombosis (p=0.003, log rank test). This finding is in accordance with previous studies, 
suggesting that patients with portal vein thrombosis have worse overall survival, 
compared to patients without portal vein thrombosis(Georgiades, Hong, D'Angelo, & 
Geschwind, 2005). 
 
5.1.2.2.  Longest uni-dimensional tumor size 
Our study indicates that the longest uni-dimensional baseline tumor size is an 
independent predictor of overall survival. Compared to patients with tumor longest 
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diameter of less than 5 cm, patients with tumors 5-7.99 cm had a higher hazard of death 
(HR= 3.16, 95% CI=1.27-7.90, p=0.01), after adjusting for etiology of cirrhosis. 
Accordingly, patients with baseline tumor sizes larger than 8 cm and smaller than 12 cm 
had a similarly higher hazard of death compared to patients with baseline tumor sizes 
smaller than 5 cm (HR=3.37, 95% CI=1.37-8.30, p=0.01), after adjusting for etiology of 
cirrhosis. Patients with tumors larger than 12 cm had a much higher hazard of death 
compared to patients with baseline tumor sizes smaller than 5 cm (HR=7.45, 95% CI= 
2.46-22.53, p<0.0001), after adjusting for etiology of cirrhosis. This finding suggests that 
tumors with longest diameters between 5 and 12 cm may show a similar biological 
behavior. After regrouping patients according to the cut-off value of 5 cm in uni-
dimensional tumor size, patients with smaller tumors had a statistically significant higher 
hazard of death (adjusted HR=3.60, 95% CI=1.60-8.09, p=0.002). The prognostic impact 
of uni-dimensional tumor size measurements on overall survival has been demonstrated 
in rather few studies, as most research studies focus on documenting tumor response by 
the established RECIST and mRECIST. While uni-dimensional measurements are 
thought to be a poor surrogate for tumor volume and tumor size measurements are 
challenging to reliably reproduce, we demonstrated that the cut-off value of 5 cm is an 
independent prognostic factor of overall survival. This cut-off value, however, already 
part of the Milan criteria for liver transplantation, represents the distinct biology of small 
HCC tumors(Yao et al., 2002). 
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5.2. Statistical implications 
 5.2.1. Comparison of time-dependent and time independent multivariable Cox 
regression analyses 
Cox proportional hazards regression analyses are very common in medical research 
and particularly, in oncology. However, these analyses do not usually utilize all of the 
available information and are often restricted to data collected at baseline. In clinical 
oncologic practice, individual clinical, biochemical and imaging data are routinely 
collected for each patient at frequent time points after study entry, however, this added 
information is rarely examined in relation to survival. Yet, a key clinical question is that 
of prognosis, especially in regards to the variation in prognostic values over time. Time-
dependent multivariable Cox regression is a robust option for assessing the temporal 
dynamics of covariate effects on right-censored failure times. 
The use of time-dependent Cox models in this work resulted in identification of 
different predictors of overall survival than those identified in time-independent models, 
probably due to the fact that the latter do not account for changes in tumor response, 
clinical performance status and liver function over time. If only baseline measurements 
are available, then ECOG score of zero, absence of baseline PVT and smaller baseline 
tumor size are significantly associated with longer overall survival, after adjusting for 
other potential confounders.  In the time-dependent analysis where covariate values may 
vary over time, lower ECOG score and CTP score of A are significantly associated with 
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longer overall survival; PVT and tumor size are not longer significantly associated with 
survival.   This work suggests the importance of collecting both ECOG score and CTP 
score, if possible, over the course of treatment in predicting future prognosis.   .  
5.3.  Study limitations 
One major study limitation is the retrospective nature of the analysis. Obtaining 
the clinical data via chart review is limited by access and accuracy of the data. 
Additionally, as a retrospective study, it is subject to selection bias and incomplete data 
collection. 
For this study, we performed complete case analysis and excluded patients with 
missing values of tested covariates. This resulted in exclusion of useful data that had 
been recorded. When data can be assumed as missing at random, complete case analysis, 
however, is thought to provide unbiased estimates of the parameters of interest, although 
with reduced precision. Alternative methods of dealing with missing data need to be 
further explored, so as to identify patterns of missingness as well as missing data 
mechanisms.  
5.4.  Study Strengths 
 A major strength of this study is the assessment of longitudinally collected patient 
data. Important events that may occur during follow-up, such as a change in performance 
status or in liver function should not be ignored, as they may lead to biased results. 
Assessment of longitudinally collected data in patients with HCC treated with TACE has 
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not been extensively reported and this study may aid as a guide for clinicians who wish to 
further explore the wealth and value of such routinely available data. 
Studies with applications of time-dependent Cox models are still few, but have 
increased over the past years. However, several of these, have dealt only with the special 
case of a single time-varying variable. In this study, we simultaneously explored several 
time-varying variables in time-dependent Cox models that can handle well both 
categorical and continuous variables. The simultaneous exploration of time-varying 
covariates related both to the tumor and liver damage is essential in this category of 
cancer patients, where hepatocellular cancer co-exists with hepatic cirrhosis.  
5.5.  Conclusions 
In this retrospective study of 211 patients with unresectable HCC treated with 
TACE, we examined, in a subset of 119 patients with complete case analysis, the effect 
of baseline and longitudinal time-dependent predictors on overall survival. Mean overall 
survival was 18.85 months and the median was 14 months. The analysis of time-
independent Cox models revealed that portal vein thrombosis (HR= 2.47, 95% CI= 1.32-
4.64, p=0.01) and uni-dimensional tumor size greater than 5 cm (5-7.99 cm, HR= 3.16, 
95% CI=1.27-7.90, p=0.01; 8-11.99 cm, HR=3.37, 95% CI=1.37-8.30, p=0.01; >12 cm, 
HR=3.56, 95% CI= 2.46-22.53, p<0.0001) were independent baseline predictors of 
overall survival, after adjusting for hepatic cirrhosis. The analysis of time-dependent Cox 
models revealed a higher hazard of death for patients with ECOG status of 1 or 2, as 
compared to an ECOG status of 0 (time-dependent multivariable Model A, HR=1.83, 
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95% CI=1.11-3.03, p=0.02, adjusted for hepatic cirrhosis, metastases, portal vein 
thrombosis, mRECIST and CTP score, stratified by age); time-dependent multivariable 
Model B, HR=1.80, 95% CI=1.00-3.25, p=0.05, adjusted for age, ethnicity, hepatic 
cirrhosis, portal vein thrombosis, tumor size and CTP score ) and a higher hazard of death 
for patients with CTP score of B, as compared to CTP score of A (time-dependent 
multivariable Model B, adjusted HR=1.50, 95% CI=1.07-2.12, p=0.02, after adjusting for 
age, ethnicity, hepatic cirrhosis, portal vein thrombosis, tumor size and CTP score). By 
taking into account more information clustered per patient over time, time-dependent Cox 
proportional hazard models provide more accurate hazard ratio estimates of death than 
those obtained with time-independent analysis. The study of patients with unresectable 
HCC and cirrhosis treated with TACE using longitudinally collected clinical and imaging 
data in time-dependent Cox models may provide more reliable information about their 
prognosis.  
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CHAPTER 6. FUTURE WORK 
6.1. Multiple Imputation for Missing Data 
In this study, as noted in the limitations, we included only cases with complete 
covariate information over time in order to set up and assess the time-dependent Cox 
models. We, therefore, excluded 43.6% of patients from the original dataset, resulting in 
a substantical loss of information. Multiple imputation methods provide a useful strategy 
for dealing with data sets with missing values. Instead of filling in a single value for each 
missing value, Rubin’s multiple imputation procedure (Rubin, 1976) replaces each 
missing value with a set of plausible values that represent the uncertainty regarding the 
correct imputed value. These multiply imputed data sets are then analyzed by using 
standard procedures for complete data and combining the results from these analyses. 
This results in valid statistical inferences that properly reflect the uncertainty due to 
missing values (Yuan, 2010).  
 
6.2. Joint Modeling Approaches 
 
Cancer studies often collect time-to-event data and repeated measurements of 
longitudinal data for each subject. Longitudinal data can be important predictors or 
surrogates of a time to event, such as overall survival. However, classical models such as 
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the linear mixed model for longitudinal data and the Cox proportional hazards model for 
time-to-event data do not consider the dependencies between these two different data 
types (longitudinal and time-to-event data). A powerful method that takes into account 
the dependency and association between longitudinal data and time-to-event data is joint 
models for longitudinal and time-to-event data. Joint models for longitudinal and time-to-
event data are models that bring these two data types together (simultaneously) into a 
single model to better assess the effect of a treatment(Crowther, Abrams, & Lambert, 
2013; Ibrahim, Chu, & Chen, 2010; Rizopoulos, 2013; D. Zhang et al., 2014). As a result 
of the rapid development of clinical and genetic biomarkers in clinical trials, joint 
modeling has gained in popularity in recent years because it reduces bias in estimates of 
the treatment effects and provides improvements of efficiency in the assessment of 
treatment effects and other prognostic factors. 
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List of Abbreviations 
AASLD: American Association For The Study Of Liver Diseases  
BCLC: Barcelona Clinic Liver Cancer 
CI: Confidence Interval 
CR: Complete Response 
CT: Computed Tomography 
CTP: Child-Turcotte-Pugh 
DEB: Doxorubicin-Eluting Beads 
EDA: Exploratory Data Analysis 
Gd: Gadolinium 
GDA: Gastroduodenal Artery 
GRE: Gradient Recall Echo 
HAE: Hepatic Arterial Embolization 
HCC: Hepatocellular Carcinoma 
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HIPAA: Health Insurance Portability and Accountability Act 
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MRI: Magnetic Resonance Imaging 
OR: Odds Ratio 
P-H: Proportional Hazards 
PD: Progressive Disease 
PR: Partial Response 
RCT: Randomized Controlled Trial 
RECIST: Response Evaluation Criteria In Solid Tumors  
SD: Stable Disease 
SE: Standard Error 
SMA: Superior Mesenteric Artery 
TACE: Transcatheter Arterial Chemoembolization 
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